



NATIONAL CANCER REGISTRY

Division of the National Health Laboratory Service



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

EKURHULENI POPULATION- BASED CANCER REGISTRY 2022 REPORT

Johannesburg, South Africa, March 2024

Copyright © 2024

Citation:

**National Cancer Registry, South Africa. Ekurhuleni Population-Based Cancer Registry
2022 Report. <https://www.nicd.ac.za/centres/national-cancer-registry/>**

Compiled by:

Babongile Ndlovu (Epidemiologist)

Dr Judith Mwansa-Kambafwile (Senior Epidemiologist)

Dr Mazvita Muchengeti (Head of Department)

Ekurhuleni Population-Based Cancer Registry Surveillance Officers:

Clarence Sibiya

Londiwe Nyembe

Mapule Makama

Nelisiwe Fakude

Nomthandazo Dube

Phelade Kale

Simphiwe Javu

Sphiwe Mpangani

Ekurhuleni Population-Based Cancer Registry

National Cancer Registry, National Health Laboratory Service

1 Modderfontein Road, Sandringham

Johannesburg

South Africa

2131

Tel: +27 11 555 0548

Fax to email: +27 11 386 6516

Website: <https://www.nicd.ac.za/centres/national-cancer-registry/>

DISCLAIMER

This report includes all reported cancer cases for Ekurhuleni residents diagnosed from 1st January 2022 to 31st December 2022 as recorded in the Ekurhuleni population-based cancer registry (EPBCR). The information reflects the data at the time of closing the 2022 database for cleaning and analysis on the 31st of January 2024. The EPBCR continues to receive and collect additional data; therefore, the data may be updated as and when necessary. Requests for data should be directed to the NCR administrator, Ms Evelyn Nkosi, EvelynN@nicd.ac.za.

TABLE OF CONTENTS

DISCLAIMER	iii
TABLE OF CONTENTS	iv
LIST OF TABLES	v
LIST OF FIGURES	v
LIST OF APPENDICES	v
FOREWORD	viii
EXECUTIVE SUMMARY	ix
INTRODUCTION.....	1
METHODS	3
Data sources.....	3
Data collection and processes.....	6
Confidentiality	8
Statistical analysis.....	9
RESULTS	10
Overall cancer incidence	10
Comparison with the years 2017, 2018, 2019, 2020, 2021 & 2022	16
Childhood cancer incidence	19
Data Quality Indicators.....	20
DISCUSSION.....	22
CONCLUSION.....	24
ACKNOWLEDGEMENTS.....	25
REFERENCES	27
APPENDICES	28

LIST OF TABLES

Table 1: Summary statistics for all cancers in men, EPBCR 2022.....	11
Table 2: Summary statistics for all cancers in women, EPBCR 2022.....	12
Table 3: Childhood cancers, EPBCR 2022	19
Table 4: Percentage of cases Morphologically Verified (MV), Diagnosed Clinically Or Diagnosed By Death Certificate Only (DCO), EPBCR 2022.....	20

LIST OF FIGURES

Figure 1: Ekurhuleni population-based cancer registry data sources map, 31 December 2022	5
Figure 2: Ekurhuleni population-based cancer registry data flow diagram, 2017-2022.....	7
Figure 3: Percentage of cancer cases by gender and race, EPBCR 2022.....	10
Figure 4: Frequency of most common cancers in males, EPBCR 2022	13
Figure 5: Age standardised incidence rates for most common cancers in males, EPBCR 2022	14
Figure 6: Frequency of most common cancers in females, EPBCR 2022	14
Figure 7: Age-standardised incidence rates for common cancers in females, EPBCR 2022..	15
Figure 8: ASR for top 5 cancers in men by population group, EPBCR 2022.....	15
Figure 9: ASR for top 5 cancers in women by population group, EPBCR 2022	16
Figure 10: ASRs for most common cancers in men, 2017-2022.....	17
Figure 11: ASRs for most common cancers in women, 2017-2022.....	17
Figure 12: Number of cancer cases reported by year and gender, EPBCR 2017-2022	18

LIST OF APPENDICES

Appendix 1: list of data sources.....	28
Appendix 2: Suth African cancer notification form.....	30
Appendix 3: Tables of incidence by site, sex, age group and population, 2022	31

ACRONYMS AND ABBREVIATIONS

AFCRN	: African Cancer Registry Network
ASR	: Age-Standardised Incidence Rate

CIDERU	: Cancer & Infectious Diseases Epidemiology Research Unit
CNS	: Central Nervous System
DoH	: Department of Health, South Africa
DHA	: Department of Home Affairs, South Africa
EPBCR	: Ekurhuleni Population-Based Cancer Registry
IACR	: International Association of Cancer Registries
IARC	: International Agency for Research on Cancer
ICCC	: International Classification of Childhood Cancer
ICDO-3	: International Classification of Diseases for Oncology Third Edition
INCTR	: International Network for Cancer Treatment and Research
KZN PBCR	: Kwazulu-Natal Population-Based Cancer Registry
KZN	: KwaZulu-Natal
LMIC	: Low- or Middle-Income Country
NCDs	: Non-Communicable Disease
NCR	: National Cancer Registry, South Africa
PBCR	: Population-Based Cancer Registry
POPI Act	: Protection of Personal Information Act, South Africa
SA	: South Africa
SAMRC	: South African Medical Research Council
SAOC	: South African Oncology Consortium
STATSSA	: Statistics, South Africa
UICC	: Union for International Cancer Control
UP	: University of Pretoria
WHO	: World Health Organization

WSP : World Standard Population

CIDERU : Cancer and Infectious Disease Epidemiology Research Unit

SACCSG : South African Children's Study Cancer Group

FOREWORD

It gives me great pleasure to make public the 2022 annual report of the Ekurhuleni Population-Based Cancer Registry (EPBCR).

The current report on the EPBCR culminates from continued support from the National Department of Health, the National Institute for Communicable Diseases, the National Health Laboratory Service, and the work of the National Cancer Registry (NCR). The NCR also received support from Takeda Pharmaceuticals to support population-based cancer registration. This is the sixth report to be produced for the EPBCR; previous reports have covered the years 2017 to 2021. While this report provides essential information for healthcare planning locally, the vision for the EPBCR has always been to reach benchmark international standards to report South Africa's cancer incidence rates to the International Agency for Research on Cancer (IARC). With each successive year of operations, the EPBCR has achieved progressively better data quality.

In the 2023/2024 financial year, post COVID-19 pandemic, access to hospitals for surveillance officers has improved significantly. The new challenge of high stages of load shedding has made the cancer surveillance work very difficult, with some hospitals not excluded from power cuts and persistent network connectivity issues in some healthcare facilities. However, it is due to the resilience of the staff of the EPBCR that adequate data were collected for the year 2022 resulting in the publication of this report. I would like to commend the staff and stakeholders of the EPBCR for their ongoing commitment to cancer surveillance during these challenging times.



Dr Mazvita Muchengeti

(Head of the Department, National Cancer Registry)

Date: 31 March 2024

EXECUTIVE SUMMARY

It has been more than a decade since the enactment of Regulation No. 380 of the National Health Act (Act 61 of 2003), which formally established the National Cancer Registry (NCR) as the delegated agency for the collection of cancer surveillance information on behalf of the National Department of Health (NDoH). This regulation made cancer a reportable disease with every healthcare worker obliged to report confirmed cancers to the NCR. In addition, it mandated the NCR to establish population-based cancer registration for the country which led to the establishment and successful implementation of the Ekurhuleni population-based cancer registry (EPBCR) as a pilot site for population-based cancer surveillance in South Africa (SA).

Despite the NCR operating pathology-based cancer registration since 1986, population-based cancer registration (PBCR) remains the gold standard for cancer surveillance worldwide. It is through comprehensive and quality cancer data that can only be generated by PBCR that the country can effectively drive cancer policy, decision-making, and intervention programmes aimed at reducing cancer cases and deaths. The EPBCR has yielded six years of data since its implementation in 2017.

This report details the sixth year of population-based cancer registration in Ekurhuleni metropolitan municipality, Gauteng province of SA. This includes cancers that were diagnosed between 1st January and 31st December 2022. Data collection for these cancers was conducted in the years 2023 and 2024. Methods of data collection endorsed by the International Agency for Research on Cancer, the International Association of Cancer Registries and the African Cancer Registry Network were employed.

A total of 4116 new cancer cases were registered for the year 2022. The most common cancers registered were prostate, colorectal and lung cancers among males and breast, cervix and colorectal cancer among females. Among children (0-14 years) there were 33 cases registered for 2022. Lymphomas were the most common cancer in children.

The overall case finding and data collection for the year 2022 decreased by 11% compared with 4631 in 2021. A major challenge is the misinterpretation of the Protection of Personal Information Act (POPI Act), a legislation regulating the processing of personal information by public and private bodies, resulting in facilities being less willing to report cancer data in fear of breaching the act. Despite the challenges encountered by the EPBCR surveillance officers in data collection, there has been an improvement in stakeholder relations. The NCR managed to convene cancer surveillance stakeholders (public and private healthcare facility managers,

patient managed care programmes e.g. ICON Oncology) in a workshop that aimed to address gaps in cancer surveillance in SA. During this workshop stakeholders proposed a working group that will be responsible for developing cancer surveillance strategies. Institutions expressed their interest in working with the NCR in ensuring progress in strengthening the cancer surveillance system. During this workshop the NCR also received a commitment from ICON Oncology, a private cancer patient managed care programme (that manages 60% of the private healthcare cancer data) to share data with the NCR. Since then, the ICON Oncology team has been working together in exploring safest way to share the data, trials have been done and in the next report, a major private healthcare data source will be added. The NCR also successfully submitted the 2020 data to GLOBOCAN (<https://gco.iarc.fr/today/>). This is the first time that SA data will be used in the cancer global statistics as previous SA estimations have been modelled from neighbouring countries.

This report provides valuable information for key stakeholders to guide decision-making, planning of cancer initiatives and intervention programmes, and important data for the evaluation of health interventions.

In the 2024/25 financial year, the NCR will continue to strengthen all their PBCRs (EPBCR and KZN PBCR). The main priorities will be i) to submit the revised and updated EPBCR (2017-2022) to IARC, ii) to continue to strengthen the relationship with the private sector, iii) to ensure that the NCR gets access to mortality data, and iv) to enhance the engagement with the Western Cape province to implement the PBCR in the Western Cape province.

INTRODUCTION

Cancer remains an important public health challenge and the second leading cause of death globally (1). In 2020, the World Health Organisation (WHO), International Agency for Research on Cancer (IARC) reported an estimated 19.3 million new cancer cases and about 10 million deaths worldwide (2). The distribution of cancer incidence and mortality vary significantly across different regions of the world. Low and middle-income countries (LMICs) are greatly affected and it is estimated that in 2040 about two-thirds of new cancer cases will originate in LMICs (3). The economic implications of the increasing cancer incidence and deaths are catastrophic to both individuals in the community and to the public health system (4). Proper evidence-based planning for the future to effectively inform cancer prevention and control policies, intervention programmes and strategies, depends on robust continuous cancer surveillance with quality data (3). It was recognised by many governments during the 2011 United Nations resolution on Non-Communicable Diseases (NCDs) and WHO Global Action for the prevention and control of NCDs for 2013-2020, that population-based cancer registries (PBCRs) are vital components for cancer prevention and control (5). The PBCR gathers information about all cancer cases and deaths for residents within a well-defined geographical area over some time (6). The PBCR is the only tool that can provide the best estimation of the true burden of cancer, monitor epidemiological trends, as well as predict the future cancer burden of the country (6).

In 2011, the IARC in partnership with international communities launched the Global Initiative for Cancer Registry Development (GICR) to accelerate PBCR coverage and quality data improvements across the globe (7).

Despite the efforts made by the IARC, there are an estimated 700 cancer registries across the world which cover only about 21% of the world's population (8). In the African region, the PBCR coverage is estimated at 11%. To improve PBCRs coverage and effectiveness of cancer surveillance in sub-Saharan Africa, the International Network for Cancer Treatment and Research (INCTR) established and launched the African Cancer Registry Network (AFCRN) in 2012 (8).

The South African government has made efforts to support the development of PBCR in the country. In 2011, the South African Department of Health enacted Regulation No. 380 of the National Health Act (Act 61 of 2003), which formally established the National Cancer Registry (NCR) as its delegated agency for the collection of cancer surveillance information (3). This

regulation made cancer a reportable disease with every healthcare worker obliged to report confirmed cancers to the NCR (3,4). In addition, it mandated the NCR to establish PBCR for the country. After consultation with local and international cancer surveillance experts, it was decided that a minimum of four population-based cancer registries will be required to confidently extrapolate national cancer incidence. The NCR established the Ekurhuleni Population-Based Cancer Registry (EPBCR) in Gauteng, as the first urban population-based cancer surveillance site in the country in 2017. The NCR will continue to strengthen the PBCR by ensuring that its data meets international standards. The NCR will also continue to implement other PBCRs in SA, capacity building and strengthening stakeholder relationships. The EPBCR (2017-2021) data were evaluated internally using the IARC tools (<http://www.iacr.com.fr/files/IARCCrgToolsSetup213.zip>) and submitted to the African Cancer Registry Network (AFRCN) and positive feedback has been received. On 28 February 2023, the KwaZulu-Natal (KZN) PBCR was officially launched in Durban. The KZN PBCR covers the health districts of eThekweni, Umgungundlovu, Zululand and King Cetshwayo in KZN Province of the country. This was achieved through the relationship established between the NCR and the Cancer and Infectious Disease Epidemiology Research Unit (CIDERU) of the University of KwaZulu-Natal (UKZN) to establish the population-based cancer registry in KZN Province. The KZN PBCR is the second PBCR from the four required registries as per the mandate. Engagements with the Western Cape Province started in 2023, for the inception of a third PBCR.

The NCR has partnered with the University of Pretoria (UP), School of Medicine to build capacity and develop an interest in oncology services. The EPBCR hosted the UP third-year Medical students in 2022 and 2023 and rotated them throughout the EPBCR data sources to gain access and experience in cancer surveillance in SA as well as to be involved in paediatric cancer surveillance. This initiative was designed to help students gain an understanding and develop an interest in oncology services.

The NCR had a meeting with the Ekurhuleni Department of Health District team in January 2023 to strengthen our strategic partnership and to ensure all the possible data sources can be found. The NCR has initiated engagement with the private sector including the South African Oncology Consortium (SAOC) to ensure adequate access of both private and public sector data sources. This is the sixth cancer incidence report for the EPBCR accounting for all reported cancers diagnosed in 2022.

METHODS

The EPBCR employs cancer registration guidelines and strategies developed by the International Association of Cancer Registries (IACR), the International Agency for Research on Cancer (IARC) and the African Cancer Registry Network (AFCRN). The EPBCR employs both passive (receives reports from facilities) and active surveillance (sends surveillance officers to facilities to collect information from different sources), collecting data on all cancer patients residing in Ekurhuleni metropolitan municipality diagnosed by clinical, radiological, pathology or any other means of investigation.

Data sources

i. Government and Private Hospitals/Healthcare Facilities

The EPBCR has multiple data sources. The data sources extend beyond the borders of the Ekurhuleni metropolitan municipality due to the nature of the South African healthcare referral system. The municipalities do not often have all levels of care (level 1: Primary healthcare clinic, Community healthcare centre, District hospital, level 2: Regional hospital, level 3: Provincial tertiary hospital, and level 4: Central hospital and Specialised hospital) within its borders (9). Therefore, patients may be referred out of the municipality to access further diagnosis and management. Secondly, South African patients are a highly mobile population and have the freedom to choose the healthcare facility they prefer, which may not necessarily be within the borders of the district in which they reside.

In addition to the public healthcare facilities, South Africa also has a large and well-resourced private healthcare industry. Sixteen per cent of the South African population has medical health insurance and is thus able to access healthcare in private healthcare facilities. Therefore, to obtain complete reporting from the Ekurhuleni District's population, the EPBCR also collects data from private hospitals, and clinicians in independent private practice (See Appendix 1 for a comprehensive list of data sources).

ii. Laboratories, Oncology Networks and Associations

SA has an expansive network of both public and private laboratories. An estimated 80% of the SA's population is serviced by NHLS, which has over 268 laboratories in nine provinces of SA (10). The other estimated 20% of the population is covered

by private laboratories which include but are not limited to Ampath, Pathcare and Lancet laboratories. Both public and private laboratories send electronic reports of patients diagnosed with cancer to the NCR's national pathology surveillance programme. The surveillance officers use all the pathology reports received from laboratories together with other data tools (medical files, hospital register, pharmacy list etc.) to identify, trace and register patients from Ekurhuleni metropolitan municipality into the EPBCR.

In addition, The South African Children's Study Cancer Group (SACCSG) and the South African Oncology Consortium (SAOC) report their relevant data for residents of Ekurhuleni to the NCR. The surveillance officers use these data sources to consolidate missing information for patients already registered in the EPBCR database or to trace and notify the patient in conjunction with other data tools from different data sources. Finally, surveillance officers use hospital registers, patient files and mortuary records to identify new patients not already recorded in an existing database available to the NCR.

iii. The Hospice

The surveillance officers visit hospices at regular intervals to consolidate information missing for patients already registered from other data sources such as hospitals, as well as to report any new patients identified.

iv. Vital Statistics (Death Registration)

The Department of Home Affairs (DHA) is the custodian of vital statistics for SA. Statistics South Africa (STATS SA) also has cleaned vital statistics data for South Africans that can be used to consolidate vital status (i.e. dead/alive) in the EPBCR. However, STATS SA is unable to legally share patient-level data with other official organisations. To compensate for the challenge, the surveillance officers visit the mortuaries within healthcare facilities to trace and report cases of cancer for patients who may have been missed while alive.

Figure 1 below illustrates the spatial distribution of the data sources for EPBCR as of 31 December 2022.




Figure 1: Ekurhuleni Population-based cancer registry data sources map, 31 December 2022

Data collection and processes

The EPBCR uses both active and passive methods of case finding.

Active case finding:

- The surveillance officers visit healthcare facilities to review electronic and or physical records of patients such as patient files, admission registers, pathology reports, radiology reports, death registers, outpatient registers, pharmacy registers and clinicians' statistical records to notify confirmed cancer cases on the cancer notification forms.

Passive case finding:

- As mentioned above, both the South African Children's Study Cancer Group (SACCSG) and the South African Oncology Consortium (SAOC) passively provide data to the NCR for the Ekurhuleni district.

Inclusion criteria for both active and passive case-finding methods:

- All confirmed cancer cases, in persons who are residents of the Ekurhuleni metropolitan municipality, diagnosed from 1st January to 31 December of the relevant year must be reported to the registry.
- Cancer cases include:
 - Cases considered malignant in the morphology section of the International Classification of Diseases for Oncology (ICD-O); behaviour code-3 are reported to the registry.
 - Cancers in metastatic sites (for example, lymph nodes) are registered with the primary tumour site topography. If this is not known, it is registered as an unknown primary site.

The surveillance officers extract data/variables required (See Appendix 2: South African Cancer Registration Form) from data sources such as medical records and code the cancer diagnosis according to the International Classification of Diseases for Oncology 3rd edition (ICDO-3) for topography and morphology. A pathology report, where available, is filed with the corresponding notification form. Reports are filed according to the date and facility of diagnosis.

The files are then captured onto the RedCap system. The NCR uses REDCap instead of the IARC-recommended CanReg system because CanReg did not meet the current data processing requirements, such as large storage capacity, simultaneous multiple users and virtual network use.




Figure 2: Ekurhuleni Population-Based Cancer Registry data flow diagram, 2017-2022

The captured files are sent to the surveillance manager for quality assurance and quality control. The surveillance manager uses both the physical notification forms and electronic records on RedCap for each cancer case to check for duplicates, completeness, and consistency. The files are stored in a locked cabinet for 20 years as per the South Africa Protection of Personal Information Act (POPI Act) before they are permanently destroyed (11). The complete, quality-assured dataset is extracted per year (1st January to 31st December for each year) for cleaning and analysis using Stata software. The analyzed data is then used for annual incidence reports, teaching/training, and research purposes. Figure 2, above illustrates the data processing and flow for the EPBCR.

Confidentiality

The NCR adheres to the NHLS, the IARC/IACR guidelines and the POPI Act to ensure the preservation of privacy during the EPBCR surveillance process (11). Request to use de-identified individual-level EPBCR data by entities/individuals is sought in writing to the NCR. Ethics approval is required before data is granted. The statistics of cancer data are released in an aggregated format through the annual reports published on the NCR website.

Statistical analysis

The results are presented as:

- the number of new cancer cases,
- the percentage of all new cancer cases,
- Age-standardised incidence rate (ASR) per 100,000 and
- the lifetime risk

The results are further stratified by:

- sex (Male and Female),
- population group (Black, White, Asian and Coloured) and
- age groups (5-year interval, e.g.0-5 years, 5-10, 10-15, etc.).

For age standardization, the Segi World Standard Population (WSP) is used as per international cancer registration norms. STATS SA mid-year population data for Ekurhuleni metropolitan municipality is used as a denominator.

The calculation methods are as follows:

$$\text{Crude} = \frac{\text{Number of new cases}}{\text{Mid-year population}} \times 100,000$$

$$\text{WSP weighting} = \frac{\text{WSP (for each age group)}}{\text{Total WSP for all age groups}} \times 100,000$$

$$\text{ASR} = \text{Crude} \times \text{WSP weighting}$$

RESULTS

Overall cancer incidence

A total of 4116 cancer cases were registered by the EPBCR for the year 2022, with 1741 cases (42.3%) occurring in males and 2375 (57.7%) occurring in females. Benign growths, in-situ lesions and cancers of unknown behaviour were excluded from the data collection and analysis.

Figure 3 below shows the percentage of cancer cases diagnosed in 2022 by gender and race. Forty-three per cent of cases were diagnosed among the White population, 54% among the Black population, while 1% was diagnosed among the Coloured and Asian population groups, respectively.




Figure 3: Percentage of cancer cases by gender and race, EPBCR 2022.

Tables 1 and 2 illustrate a detailed tabulation of cases registered in 2022 for males and females. The tables show the total number of cases registered, crude rates per 100 000 population, age-adjusted incidence rates per 100 000 population, and lifetime risk for each cancer. Appendix tables further elaborate on these data by demonstrating frequency, age-standardised and age-specific incidence rates by population group and gender.

Table 1: Summary statistics for all cancers in Men, EPBCR 2022

SITE	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites	1741	106.01	107.81	12	8
All sites but skin	1362	82.93	84.28	9	11
Prostate	426	25.94	27.53	4	27
Basal cell carcinoma	372	22.65	23.12	3	39
Squamous cell carcinoma of skin	132	8.04	8.18	1	115
Colorectal	112	6.82	7.01	1	135
Primary site unknown	84	5.11	5.32	1	170
Lung	71	4.32	4.25	0	209
Melanoma	46	2.80	2.84	0	298
Bladder	45	2.74	2.79	0	324
Non Hodgkin lymphoma	44	2.68	2.54	0	409
Oesophagus	31	1.89	1.83	0	458
Larynx	27	1.64	1.72	0	501
Liver & Bile duct	25	1.52	1.49	0	529
Kaposi Sarcoma	28	1.70	1.45	0	815
Hodgkin lymphoma	24	1.46	1.45	0	815
Stomach	22	1.34	1.22	0	867
Anus	19	1.16	1.08	0	821
Skin other	17	1.04	1.05	0	810
Leukaemia	16	0.97	0.96	0	895
Kidney	15	0.91	0.95	0	908
Naso-Oropharynx	16	0.97	0.94	0	926
Tongue	14	0.85	0.90	0	870
Myeloma	14	0.85	0.85	0	1049
Pancreas	14	0.85	0.83	0	1068
Brain, CNS	12	0.73	0.77	0	1095
Penis	12	0.73	0.68	0	1159
Breast	11	0.67	0.68	0	1064
Ill defined	11	0.67	0.63	0	1595
Mouth	10	0.61	0.62	0	1760
Testis	13	0.79	0.60	0	1636
Eye	10	0.61	0.59	0	1948
Other specified	8	0.49	0.50	0	1922
Connective tissue	7	0.43	0.44	0	2482
Bone	6	0.37	0.41	0	3892
Mesothelioma	6	0.37	0.39	0	2866
Thyroid	5	0.30	0.24	0	3092
Lip	4	0.24	0.23	0	6192
Small intestine	4	0.24	0.22	0	4774
Salivary gland	3	0.18	0.18	0	4808
Endocrine	2	0.12	0.15	0	6921
Haematology other	2	0.12	0.12	0	6757
Burkitt lymphoma	1	0.06	0.05	0	33334

Table 2: Summary statistics for all cancers in Women, EPBCR 2022

SITE	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites	2375	136.75	143.34	14	7
All sites but skin	2095	120.63	123.30	12	8
Breast	590	33.97	33.63	4	27
Cervix	587	33.80	31.92	3	29
Basal cell carcinoma	273	15.72	19.64	2	51
Squamous cell carcinoma of skin	90	5.18	7.63	1	134
Primary site unknown	107	6.16	6.55	1	145
Colorectal	101	5.82	6.33	1	184
Uterus	65	3.74	4.25	0	222
Vulva	74	4.26	3.65	0	285
Melanoma	44	2.53	2.86	0	363
Lung	36	2.07	2.60	0	365
Ovary	34	1.96	2.15	0	457
Non Hodgkin lymphoma	37	2.13	2.02	0	545
Brain. CNS	23	1.32	1.40	0	662
Oesophagus	24	1.38	1.34	0	657
Anus	26	1.50	1.30	0	716
Pancreas	18	1.04	1.18	0	769
Other specified	16	0.92	1.14	0	794
Leukaemia	17	0.98	1.09	0	818
Liver & Bile duct	18	1.04	1.07	0	967
Stomach	17	0.98	1.06	0	1064
Tongue	13	0.75	0.96	0	1159
Kidney	12	0.69	0.95	0	1138
Kaposi Sarcoma	20	1.15	0.89	0	1753
Bladder	13	0.75	0.89	0	1558
Connective tissue	13	0.75	0.77	0	1680
Vagina	15	0.86	0.76	0	1847
Thyroid	13	0.75	0.73	0	1946
Hodgkin lymphoma	11	0.63	0.61	0	1991
Eye	10	0.58	0.60	0	2084
Skin other	9	0.52	0.59	0	2039
Myeloma	8	0.46	0.50	0	2041
Naso-Oropharynx	8	0.46	0.44	0	2003
Ill defined	8	0.46	0.40	0	2618
Salivary gland	6	0.35	0.36	0	3165
Larynx	4	0.23	0.25	0	3242
Mouth	3	0.17	0.17	0	5587
Bone	3	0.17	0.15	0	4831
Endocrine	3	0.17	0.14	0	9479
Lip	2	0.12	0.12	0	8621
Mesothelioma	1	0.06	0.08	0	13699

Burkitt lymphoma	1	0.06	0.07	0	9804
Gum	1	0.06	0.06	0	7381
Small intestine	1	0.06	0.04	0	31251

Figure 4-7 below illustrates the frequency and age-standardised incidence rates of the most common cancers registered in the EPBCR in 2022 for males and females. Prostate cancer was by far the most common cancer amongst men with 426 cases and an ASR of 27.53/100 000 population. Amongst women, breast cancer was leading with 590 new cases reported with an ASR of 33.63/100 000. Figures 8 and 9 illustrate the top 5 cancers ASRs by population group. In males, the White population group had the highest ASR in prostate cancer followed Black, Asian then coloured. In females, the White population group had the highest ASR in breast cancer, followed by Black, Asian then Coloured.




Figure 4: Frequency of most common cancers in males, EPBCR 2022




Figure 5: Age Standardised Incidence Rates for most common cancers in males, EPBCR 2022




Figure 6: Frequency of most common cancers in females, EPBCR 2022




Figure 7: Age-standardised incidence rates for common cancers in females, EPBCR 2022




Figure 8: ASR for top 5 cancers in men by population group, EPBCR 2022




Figure 9: ASR for top 5 cancers in women by population group, EPBCR 2022

Comparison with the years 2017, 2018, 2019, 2020, 2021 & 2022

Figures 10 and 11 show a comparison of ASRs for common cancer cases from 2017 to 2022 by gender. Figure 12 shows comparisons of case numbers from 2017 to 2022. There was a 11% decrease in the number of cancer cases reported in 2022 (n=4116) vs the year 2021 (n=4631). Among males, there was a 17% decrease from 2105 in 2021 while among females there was a 6% decrease from 2526 in 2021. The pattern of the most common top 5 cancers age-standardised incidence rates by sex remained comparable between 2017 and 2022 with few exceptions for males where NHL and oesophagus is replaced by melanoma and bladder cancers in 2022.




Figure 10: ASRs for most common cancers in men, 2017-2022




Figure 11: ASRs for most common cancers in women, 2017-2022




Figure 12: Number of Cancer cases reported by year and gender, EPBCR 2017-2022

Childhood cancer incidence

Table 3 below shows the top 10 cancers in children aged 0-14 years in the Ekurhuleni area. Thirty-three cancers were registered in 2022 among children. Paediatric cancers accounted for 0.8% of all cancers registered in 2022. There were 17 cancers in boys and 16 cancers in girls. Leukaemia, lymphoma, CNS neoplasms, soft tissue sarcomas, retinoblastoma and nephroblastoma were the most common cancers in children.

Table 3: Childhood cancers, EPBCR 2022

Cancer	Number of cases				M/F ratio	Rates per Million Age-Specific Rates			Crude	ASR	LCL	UCL
	Age 0-4	Age 5-9	Age 10-14	All Ages		Age 0-4	Age 5-9	Age 10-14				
Leukaemia	2	2	1	5		7	8	4	6.52	6.53	2.12	15.23
Lymphoma	3	2	1	6	2	10	8	4	7.82	7.88	2.89	17.13
CNS Neoplasms	2	1	1	4	1	7	4	4	5.22	5.25	1.43	13.43
Neuroblastoma	1	0	0	1		3	0	0	1.30	1.35	0.03	7.39
Retinoblastoma	3	0	0	3	1	10	0	0	3.91	4.05	0.84	11.74
Nephroblastoma - Wilms Tumour	1	2	0	3	1	3	8	0	3.91	3.90	0.80	11.41
Bone Tumours	0	1	0	1		0	4	0	1.30	1.28	0.03	7.18
Soft Tissue Sarcomas	0	1	1	2	1	0	4	4	2.61	2.55	0.31	9.28
Germ Cell Tumours	0	0	0	0		0	0	0	0.00	0.00	0.00	4.80
Primary site unknown	1	0	1	2		3	0	4	2.61	2.63	0.32	9.46
Other, specified	4	2	0	6	2	14	8	0	7.82	7.95	2.92	17.27
All sites	17	11	5	33	7	59	43	22	43.04	43.38	11.69	124.32

Data Quality Indicators

a) Basis of Diagnosis

Table 4 demonstrates the proportion of cases that were morphologically verified (MV) using histology, cytology or bone marrow aspirate and trephine, diagnosed by clinical means or registered from death certificate-only information (DCO).

Table 4: Percentage of cases Morphologically Verified (MV), diagnosed clinically or diagnosed by Death Certificate Only (DCO), EPBCR 2022

ICD 10 Cancer Site	Cases		Basis of Diagnosis		
	No. of Cases	% Total	DCO	Clinical	MV
C00 Lip	6	0.1	0.0	0.0	100.0
C02 Tongue	27	0.7	0.0	0.0	100.0
C03 Gum	1	0.0	0.0	0.0	100.0
C06 Mouth	13	0.3	0.0	7.7	92.3
C07 Salivary gland	9	0.2	0.0	11.1	88.9
C11 Naso-Oropharynx	24	0.6	0.0	4.2	95.8
C15 Oesophagus	55	1.3	1.8	16.4	81.8
C16 Stomach	39	0.9	0.0	10.3	89.7
C17 Small intestine	5	0.1	0.0	0.0	100.0
C18-20 Colorectal	213	5.2	0.0	13.6	85.9
C21 Anus	45	1.1	0.0	13.3	86.7
C22 Liver & Bile duct	43	1.0	2.3	34.9	62.8
C25 Pancreas	32	0.8	9.4	21.9	68.8
C26,C38,C48,C57,C58,C63,C68 Other specified	24	0.6	0.0	20.8	79.2
C32 Larynx	31	0.8	0.0	3.2	93.5
C34 Lung	107	2.6	0.0	27.1	72.9
C41 Bone	9	0.2	0.0	0.0	100.0
C43 Melanoma	90	2.2	0.0	4.4	95.6
C44 Basal cell carcinoma	645	15.7	0.0	0.6	98.9
C44 Squamous cell carcinoma of skin	222	5.4	0.0	0.0	100.0
C44 Skin other	26	0.6	0.0	7.7	92.3
C45 Mesothelioma	7	0.2	0.0	14.3	85.7
C46 Kaposi Sarcoma	48	1.2	2.1	8.3	89.6
C49 Connective tissue	20	0.5	0.0	10.0	90.0
C50 Breast	601	14.6	0.3	10.6	88.9
C51 Vulva	74	1.8	0.0	9.5	90.5
C52 Vagina	15	0.4	0.0	6.7	93.3
C53 Cervix	587	14.3	0.2	4.1	95.7
C54 Uterus	65	1.6	0.0	6.2	93.8
C56 Ovary	34	0.8	0.0	58.8	41.2

C60 Penis	12	0.3	0.0	0.0	100.0
C61 Prostate	426	10.3	0.2	12.7	87.1
C62 Testis	13	0.3	0.0	15.4	84.6
C64 Kidney	27	0.7	0.0	11.1	88.9
C67 Bladder	58	1.4	0.0	3.4	96.6
C69 Eye	20	0.5	0.0	15.0	85.0
C71 Brain, CNS	35	0.9	0.0	31.4	68.6
C73 Thyroid	18	0.4	0.0	5.6	94.4
C74 Endocrine	5	0.1	0.0	0.0	100.0
C76 Ill defined	19	0.5	0.0	5.3	94.7
C80 Primary site unknown	191	4.6	1.0	25.1	73.3
C81 Hodgkin lymphoma	35	0.9	0.0	11.4	88.6
C83 Burkitt lymphoma	2	0.0	50.0	0.0	50.0
C85 Non Hodgkin lymphoma	81	2.0	0.0	27.2	72.8
C90 Myeloma	22	0.5	0.0	4.5	95.5
C92 Leukaemia	33	0.8	0.0	12.1	87.9
C96 Haematology other	2	0.0	0.0	0.0	100.0
All sites	4116	100	0.3	9.7	89.8

b) Primary site unknown (PSU)

There were 191 cases of cancer (4.6%) reported where the primary site was unspecified or uncertain from the available documentation. The rates of PSU were 5.32 and 6.55 /100 000 in men and women, respectively.

c) Age unknown

There was no record with unknown age.

DISCUSSION

This report covers the sixth year of EPBCR data reporting since 2017. The data presented, reports cancer cases that were diagnosed among residents of Ekurhuleni metropolitan municipality in Gauteng province of South Africa between 1 January and 31 December 2022. Data collection for 2022 cancer cases was conducted in the year 2023/2024 and the database was closed on 31 January 2024. In cancer surveillance, data are always collected retrospectively due to the long turnaround time for diagnosis with a universal standard of a two-year reporting lag, hence the collection of 2022 EPBCR data in 2023 and 2024.

Overall, there were 4116 cases reported by the EPBCR for the year 2022, which is a decrease of 11% from the year 2021 (4631). This slight decrease did not affect the incidence rates pattern as ASRs remained comparable with previous years. The case numbers have remained approximately ± 4000 annually, except during the COVID-19 pandemic which affected data collection negatively. This report shows that surveillance activities have returned to normal. The frequency and age-standardised incidence rates analysis of 2022 EPBCR show that the most common cancers among males were prostate, colorectal and lung, whereas among women the most common cancers were breast, cervix, and colorectal respectively. The proportions of cancers are useful for determining the burden on the country's healthcare system for screening, diagnosis, treatment and care of cancer patients. On the other hand, age-standardised incidence rates are used to compare rates of cancer between different geographic regions and populations.

The general pattern of cancer among men and women remains similar to previous years with a few exceptions such as NHL and oesophageal cancers replacing melanoma and bladder cancers in the top five cancers among men. Among children (0-14 years) there were 33 cases registered for 2022. Lymphomas were the most common cancers in children. The overall percentage of morphologically verified cancer was 89.8% (ranging from 40% to 100%) with 10.2% cases being captured from clinical and death records, indication of the importance of a PBCR in capturing non-pathologically diagnosed cancers.

These results remain significant despite the challenges encountered, notably the global COVID-19 pandemic and the misinterpretation of the POPI Act. Throughout the pandemic, various obstacles emerged, hindering the collection and interpretation of crucial data. One notable challenge was the restriction on data collection activities due to COVID-19 protocols,

which prevented data collectors from accessing healthcare facilities. Additionally, cancer services were significantly reduced to prioritize respiratory illnesses, further complicating data collection efforts. During this period, cancer data collection was hampered, resulting in a retrospective compilation of cases once services returned to normalcy. Alarming, the number of reported cancer cases decreased significantly compared to pre-pandemic figures. However, with the gradual restoration of cancer services and the resumption of data collection activities, there is optimism as numbers are steadily picking up.

Furthermore, the implementation of the POPI Act added another layer of complexity to data collection efforts. Healthcare practitioners were reluctant to share data due to concerns about breaching patient confidentiality. However, efforts are underway to address these concerns. A letter from the DOH legal department will be issued to all stakeholders clarifying that reporting cancer cases to the NCR is mandatory and does not violate the POPI Act. Failure to report cancer cases is considered a criminal offense. With these efforts, the NCR is hopeful that the reported numbers will continue to increase. Additionally, the inclusion of more data sources will enhance the comprehensiveness and accuracy of cancer statistics, ultimately aiding in better understanding and addressing the burden of cancer in the population.

Historically, due to limitations in data availability and quality, estimates provided by sources like GLOBOCAN often had to resort to extrapolations and modeling techniques, including data from neighboring countries. However, with the establishment and maturation of the EPBCR, SA now has a robust system for collecting and analyzing cancer data. The EPBCR provides comprehensive and high-quality data representing the Ekurhuleni metropolitan population. This means that for the first time, cancer statistics for SA can truly reflect the unique epidemiological landscape of the country. By utilizing data collected directly from within SA's borders, the accuracy and reliability of cancer statistics are greatly improved. This transition not only enhances our understanding of the burden of cancer within the country but also enables more informed decision-making in healthcare policy, resource allocation, and research efforts.

In the 2024/25 financial year, the NCR will continue to strengthen the EPBCR system and set a benchmark for the other PBCR in SA to gather comprehensive, representative and best-quality cancer data to inform cancer prevention and control in the country. The NCR in partnership with UKZN-CIDERU launched a KZN PBCR, and in the near future, the cancer incidence from both registries will be computed together to increase the accuracy of the

estimates. EPBCR will continue with 2023 and 2024 data collection in the year 2024 and continue to provide technical support in other cancer registries.

CONCLUSION

Population-based cancer registration is the key for countries to effectively drive cancer policy, decision-making, and intervention programmes which are aimed at reducing cancer cases and deaths. The EPBCR has progressively produced six years of quality cancer data for SA. Regardless of the challenges encountered such as the COVID-19 pandemic and misinterpretation of POPI Act, the results of the 2022 EPBCR reports are significant. The most common cancers registered were prostate, colorectal and lung cancers among males and breast, cervix, and colorectal cancer among females. Among children (0-14 years) the most common cancers were leukaemia, lymphoma, CNS neoplasms, soft tissue sarcomas, retinoblastoma and neuroblastoma. The EPBCR has set a benchmark for the implementation of future PBCRs in SA and has successfully implemented a second PBCR in KZN.

ACKNOWLEDGEMENTS

This work has been possible through seed funding provided by the South African Medical Research Council. The NCR would also like to thank the National Institute for Communicable Diseases for the continuous support in operational costs for EPBCR. The NCR would like to thank the National Department of Health for additional funding that has assisted in the continued operations of the EPBCR. The NCR would like to also acknowledge Takeda Pharmaceutical Company Limited for supporting population-based cancer registration activities in EPBCR and the launch of the KZN population-based cancer registry.

The National Cancer Registry (NCR) would also like to thank all individuals, organisations and relevant stakeholders that played a critical role in the operations of the Ekurhuleni Population-Based Cancer Registry.

African Cancer Registry Network (AFCRN)

Tambo Memorial Regional Hospital

Tembisa Regional Hospital

Steve Biko Academic Hospital

Thelle Mogoerane Regional Hospital

Union for International Cancer Control (UICC)

Vermaak Laboratories

World Health Organization (WHO)

South African Medical Research Council (SAMRC)

Ampath Laboratories

Arebaoke Hospice

Benoni Oncology Centre

Chris Hani Baragwanath Academic Hospital

Charlotte Maxeke Academic Hospital

Drs Gritzman & Thatcher Inc Laboratories

Eastrand Benoni Hospice

Edenvale Regional Hospital

Far East Regional Hospital

Gauteng Oncology Alberton Private Hospital

Gauteng Oncology Prostate-Clinic

Gauteng Oncology Linmed Private Hospital

International Agency for Research on Cancer (IARC)

International Association of Cancer Registries (IACR)

Lancet Laboratories

National Department of Health South Africa

National Health Laboratory Services

National Institute for Communicable Diseases

Pathcare Laboratories

Pholosong Regional Hospital

South African Oncology Consortium (SAOC)

South African Paediatric Oncology Network

St Francis Hospice

Stepping Stone Hospice

REFERENCES

1. International Agency for Research on-World Health Organization. World CanCer report 2008. Cancer research for cancer prevention. Vol. 199, Cancer Control. 2020. 512 p.
2. C P Wild, E Weiderpass BWS (editors). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. Available. Vol. 199, Cancer Control. 2020. 512 p.
3. ICCP. Cancer Registries ICCP Portal. ICCP. 2019.
4. WHO. Cancer key facts. 2020.
5. Assembly UNG. Resolution A/RES/65/238: Scope, modalities, format and organization of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. 2011;11759(April):1–4.
6. IARC. The role and status of population-based cancer registration. 2007;X.
7. IARC. About the GICR. 2011.
8. Omonisi AE, Liu B, Parkin DM. Population-Based Cancer Registration in Sub-Saharan Africa: Its Role in Research and Cancer Control. JCO Glob Oncol. 2020 Nov;(6):1721–8.
9. KwaZulu-Natal Department of Health. Referral system: levels of care. 2014. p. 2017.
10. NHLS. 2017/18 NHLS Annual Report. Sandringham; 2018.
11. Parliament of the Republic of south Africa. Protection of Personal Information Act, 2013 Ensuring protection of your personal information and effective access to information. 2013;(4):154.

APPENDICES

Appendix 1: List of Data Sources

PUBLIC HOSPITALS

- ❖ Charlotte Maxeke Johannesburg Academic Hospital
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Tshwane District Hospital
- ❖ Pholosong Regional Hospital
- ❖ Far East Rand Regional Hospital
- ❖ Thelle Mogoerane Regional Hospital
- ❖ Tembisa Regional Hospital
- ❖ Tambo Memorial Regional Hospital
- ❖ Edenvale Hospital

PRIVATE HEALTH FACILITIES

- ❖ Benoni Oncology Centre
- ❖ Gauteng Prostate Oncology - Morehill Clinic
- ❖ Gauteng Oncology - Benoni Oncology Centre
- ❖ Gauteng Oncology - Linmed Hospital
- ❖ Netcare Clinton Oncology
- ❖ Independent Practitioners

HOSPICES

- ❖ East Rand Hospice
- ❖ Flora Madiba Hospice
- ❖ Stepping Stone Hospice
- ❖ St Francis Hospice

SOUTH AFRICAN ONCOLOGY CONSORTIUM

- ❖ Private Oncologists


PAEDIATRIC ONCOLOGY

- ❖ CHOC Childhood cancer foundation
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Donald Gordon Medical Oncology Unit

NHLS

- ❖ CDW pathology-based cancer reports

Appendix 2: South African Cancer Notification Form

	<p>health Department Health REPUBLIC OF SOUTH AFRICA</p> <p>National Health Act, 2003 (Act No. 61 of 2003) Regulation Number 380</p>	<p>Republic of South Africa Department of Health</p> <p>CANCER REGISTRATION FORM</p>	<p>To be completed in duplicate in BLOCK LETTERS. Please mark with <input checked="" type="checkbox"/> the CORRECT box, where required. Original to be submitted to the National Cancer Register and copy to be retained: To be submitted to the National Cancer Register via: e-mail: cancer.registry@nhls.ac.za fax: 011 489 9132 / 011 489 9152 Post: P.O. Box 1038, Johannesburg, 2000.</p>
A. PARTICULARS OF INDIVIDUAL			
1. Name of facility <input type="text"/>			
USE PATIENT STICKER <i>if available</i>			
2. Surname <input type="text"/>			
3. Full names <input type="text"/>			
4. Date of birth <input type="text"/>			
5. Folder number <input type="text"/>			
6. Sex <input type="checkbox"/> Male <input type="checkbox"/> Female			
7. ID number/Passport number <input type="text"/>			
8. Race group <input type="checkbox"/> African <input type="checkbox"/> Coloured <input type="checkbox"/> White <input type="checkbox"/> Indian <input type="checkbox"/> Other _____			
9. Area of residence			
9.1 City/town/village <input type="text"/>			
9.2 Postal code <input type="text"/> 9.3 How long at this address? <input type="text"/> years			
Please record place of birth if not the same as current address			
9.4 City/town/village <input type="text"/>			
9.5 Postal code <input type="text"/>			
B. RISK FACTOR PROFILE			
10. Usual occupation of patient <input type="text"/> (If retired, give type of work done for most of working life)			
11. Type of industry/business <input type="text"/> (e.g Mining, farming etc)			
12. Did the patient ever smoke tobacco? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown			
13. Did the patient ever consume alcohol regularly? (that is, more than once a week) <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown			
14. HIV status <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Unknown			
C. CLINICAL AND LABORATORY DETAILS			
15. Date of diagnosis <input type="text"/>			
16. Cancer diagnosis and Histology <input type="text"/> 17. ICD-10 <input type="text"/> • <input type="text"/>			
<i>Please give all information available on the site, laterality, histology and behaviour of the tumour</i>			
18. Grade <input type="checkbox"/> Well differentiated <input type="checkbox"/> Moderately differentiated <input type="checkbox"/> Poorly differentiated <input type="checkbox"/> Unknown/Not applicable			
19. Stage <input type="checkbox"/> Primary/localised <input type="checkbox"/> Metastatic <input type="checkbox"/> Unknown/Not applicable			
20. Invasiveness <input type="checkbox"/> In-situ <input type="checkbox"/> Invasive			
21. Basis of diagnosis <input type="checkbox"/> Clinical <input type="checkbox"/> Clinical with investigation <input type="checkbox"/> Cytology/histopathology <input type="checkbox"/> Molecular <input type="checkbox"/> Death Certificate			
22. Prescribed treatment <input type="checkbox"/> Surgery <input type="checkbox"/> Radiation <input type="checkbox"/> Chemotherapy <input type="checkbox"/> Other <input type="checkbox"/> Palliation <input type="checkbox"/> Alternative <input type="checkbox"/> None			
<p>INFORMANT PARTICULARS</p> <p>Name (Print) _____</p> <p>MP/NC Number <input type="text"/></p> <p>Signature _____ Date _____</p>			<p>OFFICE CODING</p> <p><input type="text"/> • <input type="text"/></p> <p>M - <input type="text"/> / <input type="text"/> / <input type="text"/></p>

Appendix 3: Tables of Incidence by site, sex, age group and population, 2022

Tables of ASR and Crude Incidence by population group

Asian Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Breast	10	34.48	10	30.89	27.45	12.62	53.06
Uterus	4	13.79	4	12.36	12.70	3.28	34.09
Tongue	2	6.90	2	6.18	7.05	0.82	26.08
Colorectal	2	6.90	2	6.18	6.09	0.74	23.71
Primary site unknown	2	6.90	2	6.18	5.12	0.61	21.61
Skin other	1	3.45	1	3.09	4.47	0.11	22.93
Stomach	1	3.45	1	3.09	4.47	0.11	22.93
Thyroid	1	3.45	1	3.09	3.36	0.09	19.80
Non Hodgkin lymphoma	1	3.45	1	3.09	3.36	0.09	19.80
Bladder	1	3.45	1	3.09	3.36	0.09	19.80
Cervix	1	3.45	1	3.09	2.44	0.06	17.52
Other specified	1	3.45	1	3.09	2.36	0.06	17.35
Liver & Bile duct	1	3.45	1	3.09	2.31	0.06	17.25
Basal cell carcinoma	1	3.45	1	3.09	2.31	0.06	17.25
All sites	29	100	29	89.60	86.85	18.80	333.18

Black Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Cervix	518	34.72	518	38.90	41.28	37.66	45.17
Breast	400	26.81	400	30.04	32.25	29.01	35.76
Primary site unknown	65	4.36	65	4.88	5.60	4.28	7.20
Uterus	53	3.55	53	3.98	5.42	4.04	7.12
Vulva	70	4.69	70	5.26	5.00	3.84	6.42
Colorectal	45	3.02	45	3.38	3.73	2.68	5.06
Lung	23	1.54	23	1.73	2.44	1.53	3.67
Non Hodgkin lymphoma	29	1.94	29	2.18	2.18	1.43	3.20
Ovary	21	1.41	21	1.58	1.83	1.11	2.85
Oesophagus	21	1.41	21	1.58	1.64	0.99	2.56
Anus	22	1.47	22	1.65	1.53	0.93	2.40
Kaposi Sarcoma	20	1.34	20	1.50	1.29	0.77	2.07
Leukaemia	14	0.94	14	1.05	1.19	0.63	2.05
Brain. CNS	15	1.01	15	1.13	1.19	0.66	2.00
Liver & Bile duct	13	0.87	13	0.98	1.05	0.54	1.84
Squamous cell carcinoma of skin	12	0.80	12	0.90	1.03	0.49	1.88
Vagina	14	0.94	14	1.05	0.97	0.51	1.70
Other specified	11	0.74	11	0.83	0.97	0.46	1.79
Basal cell carcinoma	10	0.67	10	0.75	0.95	0.45	1.75
Stomach	10	0.67	10	0.75	0.88	0.40	1.66
Connective tissue	10	0.67	10	0.75	0.87	0.40	1.65
Kidney	8	0.54	8	0.60	0.82	0.34	1.62
Eye	10	0.67	10	0.75	0.81	0.38	1.52
Pancreas	8	0.54	8	0.60	0.73	0.30	1.48
Hodgkin lymphoma	9	0.60	9	0.68	0.61	0.27	1.21
Myeloma	6	0.40	6	0.45	0.56	0.20	1.23
Melanoma	6	0.40	6	0.45	0.53	0.19	1.18
Salivary gland	6	0.40	6	0.45	0.51	0.18	1.16
Tongue	5	0.34	5	0.38	0.50	0.15	1.17
Ill defined	6	0.40	6	0.45	0.46	0.15	1.06
Naso-Oropharynx	6	0.40	6	0.45	0.44	0.16	1.00
Bladder	5	0.34	5	0.38	0.40	0.12	0.97
Thyroid	4	0.27	4	0.30	0.27	0.07	0.76
Skin other	4	0.27	4	0.30	0.25	0.07	0.72
Endocrine	3	0.20	3	0.23	0.20	0.04	0.66
Bone	3	0.20	3	0.23	0.20	0.04	0.66
Larynx	2	0.13	2	0.15	0.14	0.02	0.58
Burkitt lymphoma	1	0.07	1	0.08	0.11	0.00	0.58
Mesothelioma	1	0.07	1	0.08	0.11	0.00	0.57
Gum	1	0.07	1	0.08	0.08	0.00	0.50
Lip	1	0.07	1	0.08	0.06	0.00	0.43
Mouth	1	0.07	1	0.08	0.05	0.00	0.41
All sites	1492	100	1492	112.10	121.13	95.49	159.27

Coloured Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	14	40.00	14	28.93	15.42	49.82	8.40
Cervix	7	20.00	7	12.91	5.18	27.83	5.50
Colorectal	4	11.43	4	10.01	2.59	25.92	5.73
Ovary	3	8.57	3	6.56	1.32	19.93	4.58
Melanoma	2	5.71	2	4.61	0.53	17.19	4.15
Lung	1	2.86	1	3.45	0.09	16.67	4.26
Brain. CNS	1	2.86	1	2.66	0.07	14.33	3.65
Vulva	1	2.86	1	1.33	0.03	11.00	2.84
Primary site unknown	1	2.86	1	1.33	0.03	11.00	2.84
Non Hodgkin lymphoma	1	2.86	1	1.14	0.03	10.62	2.75
All sites	35	100	35	72.93	25.29	44.7	204.31

White Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Basal cell carcinoma	259	31.98	259	110.86	53.84	47.01	61.63
Breast	165	20.37	165	70.62	42.73	36.12	50.39
Cervix	59	7.28	59	25.25	16.59	12.48	21.82
Squamous cell carcinoma of skin	78	9.63	78	33.39	13.63	10.59	17.65
Colorectal	50	6.17	50	21.40	10.92	7.87	15.07
Melanoma	35	4.32	35	14.98	9.48	6.24	13.97
Primary site unknown	39	4.81	39	16.69	9.16	6.35	13.08
Uterus	8	0.99	8	3.42	2.24	0.93	4.87
Lung	12	1.48	12	5.14	2.10	1.03	4.38
Thyroid	8	0.99	8	3.42	2.05	0.80	4.67
Ovary	10	1.23	10	4.28	2.01	0.90	4.37
Pancreas	10	1.23	10	4.28	1.98	0.90	4.30
Brain. CNS	7	0.86	7	3.00	1.58	0.56	3.97
Bladder	6	0.74	6	2.57	1.43	0.50	3.70
Stomach	6	0.74	6	2.57	1.32	0.46	3.53
Non Hodgkin lymphoma	6	0.74	6	2.57	1.31	0.44	3.54
Leukaemia	3	0.37	3	1.28	1.25	0.21	3.98
Anus	4	0.49	4	1.71	1.09	0.29	3.33
Other specified	4	0.49	4	1.71	1.05	0.27	3.27
Connective tissue	3	0.37	3	1.28	0.98	0.19	3.28
Hodgkin lymphoma	2	0.25	2	0.86	0.86	0.04	3.60
Tongue	5	0.62	5	2.14	0.86	0.24	2.87
Vulva	3	0.37	3	1.28	0.81	0.15	2.95
Kidney	4	0.49	4	1.71	0.76	0.18	2.78
Skin other	4	0.49	4	1.71	0.74	0.18	2.76
Oesophagus	3	0.37	3	1.28	0.70	0.12	2.78
Ill defined	2	0.25	2	0.86	0.65	0.08	2.79
Liver & Bile duct	4	0.49	4	1.71	0.58	0.15	2.46
Larynx	2	0.25	2	0.86	0.45	0.05	2.42
Small intestine	1	0.12	1	0.43	0.43	0.01	2.58
Myeloma	2	0.25	2	0.86	0.43	0.04	2.40
Naso-Oropharynx	2	0.25	2	0.86	0.41	0.05	2.34
Mouth	2	0.25	2	0.86	0.28	0.03	2.14
Vagina	1	0.12	1	0.43	0.28	0.01	2.23
Lip	1	0.12	1	0.43	0.17	0.00	2.03
All sites	810	100	810	346.70	185.15	135.47	283.93

Asian Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Colorectal	5	26.32	5	14.28	15.49	4.93	40.50
Prostate	4	21.05	4	11.42	14.52	3.94	40.25
Non Hodgkin lymphoma	1	5.26	1	2.86	7.13	0.18	34.41
Myeloma	1	5.26	1	2.86	3.98	0.10	25.67
Squamous cell carcinoma of skin	1	5.26	1	2.86	3.98	0.10	25.67
Primary site unknown	1	5.26	1	2.86	3.72	0.09	25.05
Testis	1	5.26	1	2.86	3.58	0.09	24.72
Lung	1	5.26	1	2.86	3.29	0.08	24.08
Larynx	1	5.26	1	2.86	2.76	0.07	22.97
Stomach	1	5.26	1	2.86	2.69	0.07	22.82
Melanoma	1	5.26	1	2.86	1.33	0.03	20.62
Thyroid	1	5.26	1	2.86	1.33	0.03	20.62
All sites	19	100	19	54.30	63.80	9.71	327.38

Black Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	261	35.56	261	18.25	30.56	26.79	34.68
Colorectal	58	7.90	58	4.06	5.98	4.41	7.89
Primary site unknown	45	6.13	45	3.15	4.00	2.86	5.45
Lung	35	4.77	35	2.45	2.69	1.81	3.86
Larynx	20	2.72	20	1.40	2.01	1.20	3.15
Non Hodgkin lymphoma	28	3.81	28	1.96	1.98	1.28	2.95
Basal cell carcinoma	16	2.18	16	1.12	1.81	0.98	3.01
Kaposi Sarcoma	28	3.81	28	1.96	1.69	1.08	2.58
Hodgkin lymphoma	21	2.86	21	1.47	1.45	0.87	2.32
Oesophagus	17	2.32	17	1.19	1.43	0.79	2.40
Tongue	12	1.63	12	0.84	1.12	0.56	2.01
Liver & Bile duct	12	1.63	12	0.84	1.07	0.51	1.97
Anus	13	1.77	13	0.91	1.04	0.50	1.91
Squamous cell carcinoma of skin	9	1.23	9	0.63	0.90	0.37	1.80
Stomach	11	1.50	11	0.77	0.90	0.41	1.71
Naso-Oropharynx	12	1.63	12	0.84	0.88	0.44	1.62
Penis	11	1.50	11	0.77	0.87	0.40	1.66
Breast	9	1.23	9	0.63	0.86	0.38	1.68
Leukaemia	10	1.36	10	0.70	0.81	0.37	1.56
Bladder	10	1.36	10	0.70	0.77	0.36	1.47
Eye	10	1.36	10	0.70	0.68	0.32	1.33
Ill defined	7	0.95	7	0.49	0.68	0.23	1.50
Myeloma	9	1.23	9	0.63	0.66	0.29	1.34
Brain. CNS	7	0.95	7	0.49	0.60	0.23	1.30
Other specified	7	0.95	7	0.49	0.56	0.21	1.22
Connective tissue	6	0.82	6	0.42	0.55	0.18	1.28
Kidney	6	0.82	6	0.42	0.55	0.20	1.24
Mesothelioma	4	0.54	4	0.28	0.52	0.14	1.31
Skin other	7	0.95	7	0.49	0.52	0.20	1.15
Pancreas	6	0.82	6	0.42	0.44	0.16	1.03
Mouth	5	0.68	5	0.35	0.43	0.13	1.06
Bone	4	0.54	4	0.28	0.32	0.08	0.90
Melanoma	4	0.54	4	0.28	0.32	0.07	0.91
Small intestine	3	0.41	3	0.21	0.29	0.05	0.90
Testis	5	0.68	5	0.35	0.27	0.08	0.75
Endocrine	2	0.27	2	0.14	0.20	0.02	0.75
Lip	2	0.27	2	0.14	0.13	0.02	0.58
Salivary gland	1	0.14	1	0.07	0.08	0.00	0.54
Burkitt lymphoma	1	0.14	1	0.07	0.05	0.00	0.47
All sites	734	100	734	51.36	70.67	48.98	105.24

Coloured Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	3	25.00	3	7.28	8.45	1.59	28.53
Anus	2	16.67	2	4.85	7.04	0.71	27.85
Squamous cell carcinoma of skin	1	8.33	1	2.43	6.58	0.17	30.69
Primary site unknown	2	16.67	2	4.85	4.92	0.59	22.74
Larynx	1	8.33	1	2.43	2.63	0.07	19.78
Lung	1	8.33	1	2.43	1.92	0.05	18.38
Bladder	1	8.33	1	2.43	1.92	0.05	18.38
Non Hodgkin lymphoma	1	8.33	1	2.43	1.60	0.04	17.84
All sites	12	100	12	29.13	35.06	3.27	184.19

White Males: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Basal cell carcinoma	350	36.34	350	152.04	82.40	73.61	92.17
Prostate	156	16.20	156	67.76	36.21	30.53	42.90
Squamous cell carcinoma of skin	120	12.46	120	52.13	27.27	22.41	33.13
Colorectal	49	5.09	49	21.29	11.43	8.31	15.65
Primary site unknown	35	3.63	35	15.20	9.46	6.14	14.06
Melanoma	41	4.26	41	17.81	9.39	6.65	13.22
Bladder	34	3.53	34	14.77	7.78	5.31	11.37
Lung	34	3.53	34	14.77	7.67	5.22	11.21
Non Hodgkin lymphoma	13	1.35	13	5.65	3.76	1.91	6.90
Oesophagus	14	1.45	14	6.08	3.48	1.85	6.33
Liver & Bile duct	13	1.35	13	5.65	3.24	1.68	6.03
Skin other	10	1.04	10	4.34	2.74	1.29	5.47
Stomach	10	1.04	10	4.34	2.64	1.21	5.37
Testis	7	0.73	7	3.04	2.40	0.95	5.23
Kidney	9	0.93	9	3.91	2.07	0.91	4.51
Leukaemia	6	0.62	6	2.61	1.98	0.66	4.75
Hodgkin lymphoma	3	0.31	3	1.30	1.58	0.19	5.08
Pancreas	8	0.83	8	3.48	1.42	0.61	3.52
Brain, CNS	5	0.52	5	2.17	1.31	0.41	3.60
Thyroid	4	0.42	4	1.74	1.26	0.34	3.63
Larynx	5	0.52	5	2.17	1.13	0.34	3.31
Myeloma	4	0.42	4	1.74	1.03	0.27	3.22
Mouth	4	0.42	4	1.74	1.03	0.27	3.21
Naso-Oropharynx	4	0.42	4	1.74	0.92	0.23	3.05
Anus	3	0.31	3	1.30	0.91	0.19	3.12
Ill defined	4	0.42	4	1.74	0.71	0.19	2.65
Breast	2	0.21	2	0.87	0.63	0.08	2.76
Salivary gland	2	0.21	2	0.87	0.63	0.08	2.75
Mesothelioma	2	0.21	2	0.87	0.52	0.06	2.54
Lip	2	0.21	2	0.87	0.52	0.06	2.54
Bone	2	0.21	2	0.87	0.51	0.06	2.53
Tongue	2	0.21	2	0.87	0.48	0.05	2.47
Small intestine	1	0.10	1	0.43	0.42	0.01	2.55
Penis	1	0.10	1	0.43	0.33	0.01	2.33
Haematology other	2	0.21	2	0.87	0.32	0.04	2.19
Other specified	1	0.10	1	0.43	0.30	0.01	2.28
Connective tissue	1	0.10	1	0.43	0.18	0.00	2.04
All sites	963	100	963	418.32	230.06	172.14	339.67

Age-Specific Incidence Rates /100 000 and Lifetime Risk reported as 1: x

ALL FEMALES																			
Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	3.48	5.46	3.53	12.34	10.49	21.12	71.81	121.19	161.90	274.04	229.22	383.82	470.22	490.41	726.22	1003.36	1248.94	1909.96	7
All sites but C44	3.48	5.46	3.53	12.34	10.49	20.01	68.64	116.68	157.20	253.86	210.21	345.73	419.10	387.16	561.66	769.50	851.55	1356.35	8
Anus	0.00	0.00	0.00	0.00	0.00	0.00	1.91	2.25	4.70	4.20	1.12	0.00	6.13	2.15	3.58	7.54	0.00	0.00	769
Basal cell carcinoma	0.00	0.00	0.00	0.00	0.00	1.11	1.91	3.95	4.70	20.17	17.89	38.09	47.02	103.24	160.99	233.87	397.39	553.61	51
Bladder	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.56	0.00	1.68	2.24	2.93	6.13	0.00	7.15	0.00	0.00	27.68	967
Bone	0.00	0.00	0.00	0.88	0.00	0.00	0.00	0.56	0.67	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9479
Brain. CNS	0.70	0.78	0.88	1.76	0.00	0.56	0.00	0.56	2.69	3.36	1.12	1.46	2.04	2.15	7.15	15.09	0.00	0.00	794
Breast	0.00	0.00	0.00	1.76	0.66	5.00	22.88	33.82	57.10	68.09	52.55	101.08	124.71	118.30	168.14	158.43	113.54	276.81	27
Burkitt lymphoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.58	0.00	0.00	0.00	5587
Cervix	0.00	0.00	0.00	0.00	0.66	5.56	17.16	38.89	51.06	102.55	78.27	105.48	102.22	75.28	121.63	90.53	94.62	110.72	29
Colorectal	0.00	0.00	0.00	0.00	0.00	0.56	3.81	3.38	2.02	11.77	13.42	16.11	22.49	19.36	57.24	37.72	113.54	27.68	134
Connective tissue	0.00	0.00	0.88	0.88	0.66	0.00	1.27	0.56	0.00	0.84	2.24	1.46	2.04	0.00	0.00	15.09	0.00	0.00	1847
Endocrine	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.00	0.00	1.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8621
Eye	1.39	0.00	0.00	0.00	0.00	0.00	0.64	0.56	0.00	0.84	3.35	1.46	2.04	0.00	0.00	0.00	0.00	0.00	1946
Gum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.46	0.00	0.00	0.00	0.00	0.00	0.00	13699
Hodgkin lymphoma	0.00	0.00	0.88	1.76	0.66	0.00	0.64	0.56	2.02	0.00	1.12	0.00	0.00	0.00	0.00	7.54	0.00	0.00	2618
Ill defined	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	0.67	2.52	0.00	0.00	0.00	2.15	3.58	0.00	0.00	0.00	1991
Kaposi Sarcoma	0.00	0.00	0.00	0.00	0.00	1.67	1.91	1.69	4.03	0.84	0.00	2.93	0.00	2.15	3.58	0.00	0.00	0.00	1064
Kidney	0.00	1.56	0.00	0.88	0.00	0.56	0.00	0.00	0.00	0.84	0.00	1.46	0.00	4.30	0.00	15.09	0.00	55.36	2084
Larynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	0.00	1.46	2.04	2.15	0.00	0.00	0.00	0.00	3165
Leukaemia	1.39	1.56	0.88	0.00	0.66	0.56	0.00	2.25	0.00	0.84	1.12	0.00	0.00	2.15	0.00	15.09	0.00	27.68	1753
Lip	0.00	0.00	0.00	0.00	0.00	0.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.58	0.00	0.00	0.00	4831
Liver & Bile duct	0.00	0.00	0.00	0.00	0.00	0.00	1.91	0.00	2.02	0.84	1.12	2.93	2.04	6.45	7.15	0.00	37.85	0.00	818
Lung	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	2.52	1.12	7.32	16.36	12.91	14.31	45.26	0.00	55.36	363

Melanoma	0.00	0.78	0.00	0.88	1.97	0.56	0.64	1.13	2.02	3.36	2.24	7.32	8.18	15.06	10.73	30.18	18.92	55.36	365
Mesothelioma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.04	0.00	0.00	0.00	0.00	0.00	9804
Mouth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.56	0.00	0.00	0.00	0.00	0.00	2.15	0.00	7.54	0.00	0.00	7381
Myeloma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	1.68	1.12	0.00	2.04	4.30	0.00	0.00	18.92	0.00	2039
Naso-Oropharynx	0.00	0.00	0.00	0.00	0.66	0.00	0.64	0.00	0.00	0.84	1.12	4.39	0.00	2.15	0.00	0.00	0.00	0.00	2041
Non Hodgkin lymphoma	0.00	0.78	0.00	0.00	0.00	1.11	2.54	2.25	3.36	0.84	10.06	5.86	2.04	4.30	3.58	15.09	0.00	27.68	545
Oesophagus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.82	1.34	3.36	4.47	2.93	8.18	0.00	7.15	7.54	0.00	0.00	662
Other specified	0.00	0.00	0.00	0.00	0.66	0.00	0.64	0.56	0.00	0.84	2.24	5.86	2.04	0.00	0.00	7.54	37.85	55.36	1558
Ovary	0.00	0.00	0.00	0.00	0.66	0.56	0.64	1.13	0.67	2.52	4.47	7.32	12.27	6.45	7.15	22.63	37.85	0.00	457
Pancreas	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	0.00	0.84	0.00	2.93	4.09	10.75	10.73	15.09	18.92	0.00	657
Primary site unknown	0.00	0.00	0.00	3.53	1.31	0.00	4.45	2.82	6.05	13.45	6.71	20.51	22.49	32.26	25.04	52.81	37.85	55.36	145
Squamous cell carcinoma of skin	0.00	0.00	0.00	0.00	0.00	0.56	0.00	1.69	1.34	4.20	2.24	8.79	18.40	17.21	35.77	90.53	264.93	498.25	222
Salivary gland	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.56	0.00	0.00	1.12	0.00	4.09	0.00	3.58	0.00	0.00	0.00	2003
Skin other	0.00	0.00	0.00	0.00	0.00	1.11	0.00	0.00	0.67	0.00	2.24	0.00	0.00	2.15	0.00	15.09	0.00	27.68	3242
Small intestine	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	31251
Stomach	0.00	0.00	0.00	0.00	1.31	0.00	0.00	1.13	0.00	1.68	1.12	0.00	4.09	4.30	14.31	15.09	0.00	0.00	716
Thyroid	0.00	0.00	0.00	0.00	0.66	0.00	1.91	0.00	0.00	1.68	1.12	4.39	0.00	2.15	0.00	7.54	18.92	0.00	1680
Tongue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.56	0.00	1.68	1.12	0.00	8.18	2.15	3.58	7.54	18.92	27.68	1159
Uterus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.25	2.02	1.68	5.59	16.11	22.49	30.11	28.62	45.26	0.00	27.68	184
Vagina	0.00	0.00	0.00	0.00	0.00	0.00	1.27	2.25	0.67	1.68	1.12	2.93	4.09	0.00	3.58	0.00	0.00	0.00	1138
Vulva	0.00	0.00	0.00	0.00	0.00	1.11	3.18	9.58	10.08	10.09	4.47	8.79	10.22	2.15	10.73	22.63	18.92	0.00	285

ASIAN FEMALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	0.00	0.00	0.00	0.00	0.00	0.00	54.27	32.90	192.85	198.86	268.68	140.51	305.30	207.10	243.53	1341.64	471.64	0.00	13
All sites but skin	0.00	0.00	0.00	0.00	0.00	0.00	54.27	32.90	154.28	198.86	268.68	140.51	305.30	207.10	243.53	1341.64	471.64	0.00	13
Basal cell carcinoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	519
Bladder	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	67.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	298
Breast	0.00	0.00	0.00	0.00	0.00	0.00	54.27	32.90	38.57	99.43	67.17	0.00	203.53	0.00	121.77	0.00	0.00	0.00	33
Cervix	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	121.77	0.00	0.00	0.00	165
Colorectal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	49.71	0.00	0.00	0.00	103.55	0.00	0.00	0.00	0.00	131
Liver & Bile duct	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	519
Non Hodgkin lymphoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	67.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	298
Other specified	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	471.64	0.00	
Primary site unknown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.57	0.00	0.00	70.25	0.00	0.00	0.00	0.00	0.00	0.00	184
Skin other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	447.21	0.00	0.00	
Stomach	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	447.21	0.00	0.00	
Thyroid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	67.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	298
Tongue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	49.71	0.00	0.00	101.77	0.00	0.00	0.00	0.00	0.00	133
Uterus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	38.57	0.00	0.00	70.25	0.00	103.55	0.00	447.21	0.00	0.00	95

BLACK FEMALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	3.97	6.44	4.07	12.32	8.59	22.93	78.17	143.24	191.31	299.60	226.20	379.73	390.51	373.44	509.88	611.69	236.26	499.02	8
All sites but skin	3.97	6.44	4.07	12.32	8.59	22.24	77.34	142.46	191.31	299.60	224.53	371.39	376.56	373.44	493.07	611.69	236.26	499.02	8
Anus	0.00	0.00	0.00	0.00	0.00	0.00	2.47	3.13	7.01	5.14	0.00	0.00	5.58	0.00	5.60	13.01	0.00	0.00	692
Basal cell carcinoma	0.00	0.00	0.00	0.00	0.00	0.69	0.00	0.00	0.00	0.00	0.00	8.35	8.37	0.00	11.21	0.00	0.00	0.00	699
Bladder	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.78	0.00	2.57	0.00	2.09	0.00	0.00	5.60	0.00	0.00	0.00	1812
Bone	0.00	0.00	0.00	1.03	0.00	0.00	0.00	0.78	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7118
Brain. CNS	0.79	0.92	1.02	2.05	0.00	0.69	0.00	0.78	2.00	5.14	1.66	0.00	0.00	0.00	5.60	0.00	0.00	0.00	969
Breast	0.00	0.00	0.00	2.05	0.00	6.25	24.68	40.70	59.10	73.29	51.56	104.32	94.84	105.03	151.28	169.19	70.88	187.13	29
Burkitt lymphoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.60	0.00	0.00	0.00	3572
Cervix	0.00	0.00	0.00	0.00	0.78	6.25	22.22	46.96	73.12	131.15	98.13	143.96	128.31	108.92	156.89	117.13	94.50	93.57	22
Colorectal	0.00	0.00	0.00	0.00	0.00	0.00	4.11	3.91	0.00	11.57	16.63	8.35	16.74	3.89	22.41	0.00	0.00	31.19	229
Connective tissue	0.00	0.00	1.02	1.03	0.78	0.00	0.82	0.78	0.00	1.29	1.66	0.00	2.79	0.00	0.00	26.03	0.00	0.00	1967
Endocrine	0.00	0.00	0.00	0.00	0.00	0.00	0.82	0.00	0.00	2.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5900
Eye	1.59	0.00	0.00	0.00	0.00	0.00	0.82	0.78	0.00	1.29	4.99	2.09	2.79	0.00	0.00	0.00	0.00	0.00	1394
Gum	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.09	0.00	0.00	0.00	0.00	0.00	0.00	9570
Hodgkin lymphoma	0.00	0.00	1.02	1.03	0.78	0.00	0.82	0.78	3.00	0.00	1.66	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2201
Ill defined	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.57	1.00	1.29	0.00	0.00	0.00	3.89	5.60	0.00	0.00	0.00	1499
Kaposi Sarcoma	0.00	0.00	0.00	0.00	0.00	2.08	2.47	2.35	6.01	1.29	0.00	4.17	0.00	3.89	5.60	0.00	0.00	0.00	718
Kidney	0.00	1.84	0.00	1.03	0.00	0.69	0.00	0.00	0.00	0.00	0.00	2.09	0.00	3.89	0.00	13.01	0.00	31.19	2097
Larynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	2.09	0.00	0.00	0.00	0.00	0.00	0.00	6473
Leukaemia	1.59	1.84	1.02	0.00	0.00	0.00	0.00	3.13	0.00	1.29	1.66	0.00	0.00	3.89	0.00	26.03	0.00	0.00	1387
Lip	0.00	0.00	0.00	0.00	0.00	0.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	28986
Liver & Bile duct	0.00	0.00	0.00	0.00	0.00	0.00	2.47	0.00	2.00	1.29	1.66	4.17	2.79	3.89	11.21	0.00	0.00	0.00	679
Lung	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	3.86	1.66	6.26	16.74	23.34	0.00	13.01	0.00	62.38	379
Melanoma	0.00	0.92	0.00	0.00	0.00	0.00	0.00	0.00	1.00	2.57	0.00	0.00	2.79	3.89	0.00	0.00	0.00	0.00	1791
Mesothelioma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.79	0.00	0.00	0.00	0.00	0.00	7169
Mouth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	25642

Myeloma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	2.57	0.00	0.00	2.79	7.78	0.00	0.00	0.00	0.00	1415
Naso-Oropharynx	0.00	0.00	0.00	0.00	0.78	0.00	0.82	0.00	0.00	1.29	1.66	4.17	0.00	0.00	0.00	0.00	0.00	0.00	2294
Non Hodgkin lymphoma	0.00	0.92	0.00	0.00	0.00	1.39	3.29	1.57	5.01	0.00	13.31	6.26	2.79	3.89	5.60	13.01	0.00	0.00	455
Oesophagus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.91	2.00	5.14	4.99	4.17	8.37	0.00	11.21	0.00	0.00	0.00	503
Other specified	0.00	0.00	0.00	0.00	0.78	0.00	0.82	0.78	0.00	1.29	0.00	8.35	0.00	0.00	0.00	13.01	23.63	31.19	1664
Ovary	0.00	0.00	0.00	0.00	0.78	0.69	0.82	1.57	1.00	2.57	3.33	6.26	11.16	7.78	0.00	26.03	0.00	0.00	557
Pancreas	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.57	0.00	0.00	0.00	4.17	0.00	3.89	11.21	13.01	0.00	0.00	960
Primary site unknown	0.00	0.00	0.00	4.11	1.56	0.00	3.29	2.35	7.01	15.43	8.32	16.69	13.95	23.34	28.02	52.06	0.00	0.00	162
Squamous cell carcinoma of skin	0.00	0.00	0.00	0.00	0.00	0.69	0.00	2.35	1.00	3.86	0.00	0.00	2.79	0.00	0.00	0.00	23.63	62.38	1871
Salivary gland	0.00	0.00	0.00	0.00	0.00	0.00	0.82	0.78	0.00	0.00	1.66	0.00	5.58	0.00	5.60	0.00	0.00	0.00	1386
Skin other	0.00	0.00	0.00	0.00	0.00	1.39	0.00	0.00	1.00	0.00	1.66	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4939
Stomach	0.00	0.00	0.00	0.00	1.56	0.00	0.00	1.57	0.00	1.29	0.00	0.00	5.58	3.89	5.60	13.01	0.00	0.00	1027
Thyroid	0.00	0.00	0.00	0.00	0.78	0.00	0.82	0.00	0.00	1.29	0.00	2.09	0.00	0.00	0.00	0.00	0.00	0.00	4017
Tongue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.78	0.00	0.00	0.00	0.00	8.37	3.89	0.00	0.00	0.00	0.00	1534
Uterus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.35	1.00	2.57	3.33	20.86	27.89	50.57	39.22	65.07	0.00	0.00	136
Vagina	0.00	0.00	0.00	0.00	0.00	0.00	1.65	3.13	1.00	2.57	1.66	4.17	2.79	0.00	5.60	0.00	0.00	0.00	887
Vulva	0.00	0.00	0.00	0.00	0.00	1.39	4.11	13.31	14.02	14.14	4.99	12.52	13.95	3.89	11.21	39.04	23.63	0.00	214

COLOURED FEMALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	0.00	0.00	0.00	0.00	67.71	0.00	30.61	37.95	88.64	126.98	223.34	153.32	531.80	166.90	344.73	0.00	0.00	0.00	12
All sites but skin	0.00	0.00	0.00	0.00	67.71	0.00	30.61	37.95	88.64	126.98	223.34	153.32	531.80	166.90	344.73	0.00	0.00	0.00	12
Brain. CNS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	66.48	0.00	0.00	0.00	0.00	0.00	301
Breast	0.00	0.00	0.00	0.00	33.85	0.00	30.61	18.98	44.32	31.75	74.45	0.00	332.38	55.63	0.00	0.00	0.00	0.00	33
Cervix	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	63.49	74.45	51.11	0.00	111.26	0.00	0.00	0.00	0.00	67
Colorectal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	37.22	51.11	66.48	0.00	172.36	0.00	0.00	0.00	62
Lung	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	172.36	0.00	0.00	0.00	117
Melanoma	0.00	0.00	0.00	0.00	33.85	0.00	0.00	0.00	0.00	31.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	305
Non Hodgkin lymphoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.98	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1054
Ovary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	37.22	51.11	66.48	0.00	0.00	0.00	0.00	0.00	130
Primary site unknown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	22.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	903
Vulva	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	22.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	903

WHITE FEMALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	0.00	0.00	0.00	16.66	21.68	32.70	107.17	152.60	267.32	448.82	360.37	444.38	547.74	729.29	895.50	897.90	1263.33	1589.38	5
All sites but skin	0.00	0.00	0.00	16.66	21.68	26.16	78.59	115.76	228.20	319.04	267.17	314.03	407.29	451.47	537.30	569.40	780.96	989.62	8
Anus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.41	6.21	0.00	7.02	5.79	0.00	0.00	0.00	0.00	819
Basal cell carcinoma	0.00	0.00	0.00	0.00	0.00	6.54	21.43	36.83	39.12	129.78	93.20	130.35	140.45	277.83	358.20	328.50	482.36	599.77	17
Bladder	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.21	5.93	14.04	0.00	8.53	0.00	0.00	29.99	577
Brain. CNS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.04	0.00	0.00	5.93	0.00	5.79	8.53	21.90	0.00	0.00	601
Breast	0.00	0.00	0.00	0.00	0.00	0.00	21.43	31.57	149.96	113.56	80.77	112.58	140.45	156.28	153.51	87.60	68.91	119.95	21
Cervix	0.00	0.00	0.00	0.00	0.00	6.54	0.00	47.36	19.56	91.93	55.92	11.85	28.09	23.15	42.64	32.85	22.97	29.99	62
Colorectal	0.00	0.00	0.00	0.00	0.00	6.54	7.14	5.26	19.56	21.63	6.21	35.55	28.09	40.52	93.81	54.75	137.82	0.00	76
Connective tissue	0.00	0.00	0.00	0.00	0.00	0.00	7.14	0.00	0.00	0.00	6.21	5.93	0.00	0.00	0.00	0.00	0.00	0.00	1038
Hodgkin lymphoma	0.00	0.00	0.00	8.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.95	0.00	0.00	2401
Ill defined	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.81	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1851
Kidney	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.41	0.00	0.00	0.00	5.79	0.00	10.95	0.00	29.99	1786
Larynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.02	5.79	0.00	0.00	0.00	0.00	1562
Leukaemia	0.00	0.00	0.00	0.00	7.23	6.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.99	1453
Lip	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.53	0.00	0.00	0.00	2345
Liver & Bile duct	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.58	0.00	0.00	45.94	0.00	1728
Lung	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.85	14.04	0.00	25.59	54.75	0.00	0.00	389
Melanoma	0.00	0.00	0.00	8.33	14.46	6.54	7.14	10.52	13.04	5.41	12.43	29.63	21.07	34.73	17.06	43.80	22.97	59.98	111
Mouth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.79	0.00	10.95	0.00	0.00	3455
Myeloma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.21	0.00	0.00	0.00	0.00	0.00	22.97	0.00	3221
Naso-Oropharynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.93	0.00	5.79	0.00	0.00	0.00	0.00	1707
Non Hodgkin lymphoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.26	0.00	5.41	0.00	5.93	0.00	5.79	0.00	10.95	0.00	29.99	894
Oesophagus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.21	0.00	7.02	0.00	0.00	10.95	0.00	0.00	1512
Other specified	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	12.43	0.00	7.02	0.00	0.00	0.00	0.00	29.99	1029
Ovary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.41	6.21	5.93	7.02	5.79	17.06	10.95	45.94	0.00	422
Pancreas	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.41	0.00	0.00	14.04	23.15	8.53	10.95	22.97	0.00	392

Primary site unknown	0.00	0.00	0.00	0.00	0.00	0.00	21.43	10.52	0.00	21.63	6.21	29.63	42.13	52.09	17.06	32.85	45.94	59.98	100
Squamous cell carcinoma of skin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.52	10.81	12.43	35.55	56.18	46.30	85.29	131.40	298.60	479.81	80
Skin other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.21	0.00	0.00	5.79	0.00	10.95	0.00	29.99	1667
Small intestine	0.00	0.00	0.00	0.00	0.00	0.00	7.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2802
Stomach	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.41	6.21	0.00	0.00	5.79	25.59	0.00	0.00	0.00	466
Thyroid	0.00	0.00	0.00	0.00	0.00	0.00	14.29	0.00	0.00	5.41	0.00	11.85	0.00	5.79	0.00	10.95	22.97	0.00	536
Tongue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.21	0.00	0.00	0.00	8.53	10.95	22.97	29.99	1357
Uterus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.26	6.52	0.00	18.64	0.00	7.02	0.00	8.53	0.00	0.00	29.99	436
Vagina	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.02	0.00	0.00	0.00	0.00	0.00	2850
Vulva	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.41	6.21	0.00	0.00	0.00	8.53	0.00	0.00	0.00	993

ALL MALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	8.39	3.21	0.88	8.72	4.75	6.62	23.86	38.69	76.05	140.00	177.87	332.91	435.54	531.18	726.41	964.67	900.87	749.40	8
All sites but skin	8.39	3.21	0.88	8.72	4.07	6.02	21.76	35.47	59.70	117.33	143.05	252.25	357.57	430.63	529.47	654.60	656.19	470.21	11
Anus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.93	0.82	4.93	6.22	2.93	1.90	0.00	0.00	5.74	11.12	0.00	1068
Basal cell carcinoma	0.00	0.00	0.00	0.00	0.68	0.60	1.40	2.58	15.54	22.68	34.83	79.20	74.18	100.55	193.71	310.07	244.68	279.19	39
Bladder	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.00	3.94	8.71	13.20	11.41	10.93	12.91	28.71	44.49	0.00	324
Bone	0.00	0.80	0.00	1.74	0.00	0.00	0.70	0.00	0.00	0.00	0.00	0.00	1.90	0.00	0.00	0.00	11.12	0.00	3892
Brain. CNS	2.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.64	2.96	0.00	1.47	0.00	4.37	0.00	5.74	0.00	0.00	1595
Breast	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.45	0.99	1.24	0.00	3.80	6.56	3.23	0.00	0.00	0.00	1095
Burkitt lymphoma	0.00	0.00	0.00	0.00	0.00	0.60	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	33334
Colorectal	0.00	0.00	0.00	0.00	2.03	0.00	0.00	1.93	4.09	10.85	14.93	22.00	28.53	41.53	48.43	51.68	22.24	44.08	115
Connective tissue	0.00	0.80	0.00	0.87	0.00	0.00	0.70	0.00	0.00	0.99	0.00	1.47	0.00	0.00	3.23	0.00	11.12	0.00	2482
Endocrine	0.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.19	0.00	0.00	0.00	0.00	6921
Eye	0.70	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.82	3.94	1.24	2.93	0.00	0.00	0.00	0.00	0.00	0.00	1948
Haematology other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.23	5.74	0.00	0.00	6192
Hodgkin lymphoma	1.40	0.80	0.00	0.00	0.68	0.60	0.70	1.29	3.27	3.94	2.49	1.47	5.71	2.19	0.00	0.00	0.00	14.69	815
Ill defined	0.00	0.00	0.00	0.00	0.00	0.00	1.40	0.00	0.82	0.99	0.00	0.00	0.00	4.37	9.69	5.74	11.12	0.00	1159
Kaposi Sarcoma	0.00	0.00	0.00	0.00	0.00	1.20	2.81	1.93	6.54	3.94	6.22	0.00	1.90	0.00	0.00	5.74	0.00	0.00	815
Kidney	0.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.82	0.99	3.73	4.40	3.80	4.37	0.00	11.48	0.00	0.00	1064
Larynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.64	3.94	2.49	2.93	7.61	21.86	3.23	11.48	0.00	0.00	458
Leukaemia	0.00	0.00	0.00	0.87	0.00	1.20	0.00	0.64	0.82	2.96	1.24	2.93	1.90	6.56	3.23	0.00	0.00	0.00	895
Lip	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.96	0.00	0.00	0.00	0.00	0.00	0.00	11.12	0.00	6757
Liver & Bile duct	0.70	0.00	0.00	0.00	0.00	0.00	2.11	0.00	2.45	1.97	0.00	7.33	3.80	6.56	12.91	0.00	22.24	0.00	529
Lung	0.00	0.00	0.00	0.00	0.00	0.60	0.70	3.87	2.45	13.80	9.95	10.27	15.22	19.67	19.37	45.94	0.00	0.00	209
Melanoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.58	0.82	2.96	1.24	5.87	11.41	26.23	16.14	17.23	55.61	29.39	298
Mesothelioma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.99	0.00	0.00	3.80	2.19	0.00	0.00	22.24	0.00	2866

Mouth	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.00	0.00	1.24	4.40	1.90	4.37	6.46	0.00	0.00	0.00	1049
Myeloma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.82	1.97	2.49	5.87	3.80	0.00	6.46	0.00	0.00	0.00	908
Naso-Oropharynx	0.00	0.00	0.00	0.00	0.00	0.00	1.40	0.00	1.64	0.99	2.49	5.87	3.80	2.19	3.23	5.74	0.00	0.00	926
Non Hodgkin lymphoma	0.70	0.00	0.00	0.00	0.68	0.00	0.70	4.51	3.27	6.90	11.19	4.40	5.71	10.93	0.00	11.48	0.00	14.69	409
Oesophagus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.93	2.45	2.96	2.49	11.73	7.61	4.37	6.46	22.97	0.00	0.00	501
Other specified	0.70	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.00	1.97	0.00	2.93	1.90	0.00	3.23	0.00	0.00	0.00	1760
Pancreas	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.00	0.00	0.99	0.00	7.33	0.00	4.37	9.69	11.48	0.00	0.00	867
Penis	0.00	0.00	0.00	0.00	0.00	0.00	1.40	0.00	0.82	3.94	1.24	2.93	1.90	0.00	0.00	5.74	0.00	0.00	1636
Primary site unknown	0.70	0.80	0.88	5.23	0.00	1.20	1.40	0.64	5.72	1.97	9.95	23.47	19.02	30.60	16.14	22.97	22.24	29.39	170
Prostate	0.00	0.00	0.00	0.00	0.00	0.60	0.70	3.22	10.63	13.80	27.37	71.86	176.88	166.13	277.65	235.43	166.83	146.94	27
Squamous cell carcinoma of skin	0.00	0.00	0.00	0.00	0.00	0.00	1.40	1.29	2.45	2.96	13.68	16.13	20.92	41.53	48.43	132.07	222.44	176.33	135
Salivary gland	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.82	0.00	0.00	1.47	1.90	0.00	0.00	0.00	0.00	0.00	4774
Skin other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.64	0.82	3.94	2.49	2.93	5.71	0.00	6.46	0.00	11.12	14.69	870
Small intestine	0.00	0.00	0.00	0.00	0.00	0.00	0.70	0.64	0.00	0.00	0.00	0.00	1.90	0.00	3.23	0.00	0.00	0.00	3092
Stomach	0.00	0.00	0.00	0.00	0.00	0.00	0.70	1.93	1.64	0.99	3.73	10.27	1.90	0.00	3.23	11.48	11.12	0.00	821
Testis	0.00	0.00	0.00	0.00	0.68	0.00	2.81	3.22	0.00	0.99	1.24	1.47	0.00	0.00	0.00	0.00	0.00	0.00	1922
Thyroid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.93	0.00	0.99	1.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4808
Tongue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.94	2.49	1.47	3.80	6.56	6.46	0.00	0.00	0.00	810

ASIAN MALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	0.00	0.00	0.00	0.00	134.21	0.00	0.00	44.28	0.00	37.91	110.51	67.15	88.15	247.93	597.35	987.72	0.00	1425.27	16
All sites but skin	0.00	0.00	0.00	0.00	134.21	0.00	0.00	44.28	0.00	37.91	110.51	67.15	88.15	247.93	597.35	987.72	0.00	1425.27	16
Colorectal	0.00	0.00	0.00	0.00	89.47	0.00	0.00	0.00	0.00	37.91	55.25	0.00	0.00	0.00	0.00	329.24	0.00	0.00	110
Larynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	55.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	362
Lung	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	329.24	0.00	0.00	
Melanoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	22.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	904
Myeloma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	199.12	0.00	0.00	0.00	101
Non Hodgkin lymphoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1425.27
Primary site unknown	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	123.97	0.00	0.00	0.00	0.00	162
Prostate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	88.15	123.97	199.12	329.24	0.00	0.00	49
Squamous cell carcinoma of skin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	199.12	0.00	0.00	0.00	101
Stomach	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	67.15	0.00	0.00	0.00	0.00	0.00	0.00	298
Testis	0.00	0.00	0.00	0.00	44.74	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	448
Thyroid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	22.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	904

BLACK MALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	7.94	3.57	1.03	9.54	0.75	4.37	17.66	26.71	42.86	82.44	94.35	204.14	335.97	333.63	459.47	643.96	637.81	535.47	13
All sites but skin	7.94	3.57	1.03	9.54	0.75	4.37	17.66	26.04	41.24	79.23	94.35	197.96	327.05	333.63	440.32	593.12	566.94	535.47	13
Anus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.34	0.81	4.28	2.90	4.12	0.00	0.00	0.00	16.95	35.43	0.00	1487
Basal cell carcinoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.62	3.21	0.00	4.12	5.95	0.00	12.76	50.84	70.87	0.00	724
Bladder	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.21	5.81	4.12	2.97	0.00	0.00	0.00	0.00	0.00	1242
Bone	0.00	0.89	0.00	2.12	0.00	0.00	0.74	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5334
Brain. CNS	2.38	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.62	0.00	0.00	0.00	0.00	7.25	0.00	0.00	0.00	0.00	1778
Breast	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.62	0.00	1.45	0.00	5.95	10.88	6.38	0.00	0.00	0.00	762
Burkitt lymphoma	0.00	0.00	0.00	0.00	0.00	0.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	32259
Colorectal	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.00	1.62	9.64	8.71	18.56	23.79	29.01	38.29	50.84	35.43	146.04	152
Connective tissue	0.00	0.89	0.00	1.06	0.00	0.00	0.74	0.00	0.00	1.07	0.00	2.06	0.00	0.00	0.00	0.00	35.43	0.00	3437
Endocrine	0.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.63	0.00	0.00	0.00	0.00	4525
Eye	0.79	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.81	4.28	1.45	4.12	0.00	0.00	0.00	0.00	0.00	0.00	1651
Hodgkin lymphoma	0.79	0.89	0.00	0.00	0.75	0.62	0.74	1.34	3.23	4.28	2.90	2.06	8.92	0.00	0.00	0.00	0.00	0.00	755
Ill defined	0.00	0.00	0.00	0.00	0.00	0.00	1.47	0.00	0.81	1.07	0.00	0.00	0.00	0.00	6.38	16.95	35.43	0.00	2056
Kaposi Sarcoma	0.00	0.00	0.00	0.00	0.00	1.25	2.94	2.00	6.47	4.28	7.26	0.00	2.97	0.00	0.00	16.95	0.00	0.00	737
Kidney	0.79	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.07	1.45	2.06	5.95	0.00	0.00	0.00	0.00	0.00	1767
Larynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.81	3.21	1.45	4.12	11.89	25.38	6.38	16.95	0.00	0.00	376
Leukaemia	0.00	0.00	0.00	1.06	0.00	0.62	0.00	0.67	0.81	1.07	0.00	4.12	0.00	7.25	6.38	0.00	0.00	0.00	910
Lip	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9346
Liver & Bile duct	0.79	0.00	0.00	0.00	0.00	0.00	1.47	0.00	2.43	0.00	0.00	2.06	2.97	3.63	12.76	0.00	35.43	0.00	766
Lung	0.00	0.00	0.00	0.00	0.00	0.62	0.74	3.34	1.62	10.71	7.26	4.12	14.87	3.63	12.76	16.95	0.00	0.00	336
Melanoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.81	0.00	0.00	0.00	2.97	3.63	0.00	0.00	0.00	0.00	2476
Mesothelioma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.95	3.63	0.00	0.00	35.43	0.00	2088
Mouth	0.00	0.00	0.00	0.00	0.00	0.00	0.74	0.00	0.00	0.00	0.00	4.12	0.00	7.25	0.00	0.00	0.00	0.00	1652

Myeloma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.81	1.07	2.90	6.19	2.97	0.00	0.00	0.00	0.00	0.00	1369
Naso-Oropharynx	0.00	0.00	0.00	0.00	0.00	0.00	1.47	0.00	1.62	1.07	1.45	8.25	2.97	3.63	0.00	0.00	0.00	0.00	978
Non Hodgkin lymphoma	0.79	0.00	0.00	0.00	0.00	0.00	0.74	4.01	0.81	5.35	10.16	4.12	2.97	14.51	0.00	0.00	0.00	0.00	461
Oesophagus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.00	0.81	2.14	1.45	12.37	2.97	3.63	0.00	33.89	0.00	0.00	789
Other specified	0.79	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	2.14	0.00	4.12	0.00	0.00	6.38	0.00	0.00	0.00	1419
Pancreas	0.00	0.00	0.00	0.00	0.00	0.00	0.74	0.00	0.00	1.07	0.00	8.25	0.00	0.00	0.00	0.00	0.00	0.00	1989
Penis	0.00	0.00	0.00	0.00	0.00	0.00	1.47	0.00	0.00	4.28	1.45	4.12	2.97	0.00	0.00	16.95	0.00	0.00	1400
Primary site unknown	0.00	0.89	1.03	5.30	0.00	0.62	0.00	0.67	4.85	2.14	8.71	16.50	17.84	18.13	6.38	0.00	70.87	0.00	241
Prostate	0.00	0.00	0.00	0.00	0.00	0.00	0.74	3.34	6.47	4.28	17.42	63.92	187.31	177.69	325.45	389.76	212.60	389.44	26
Squamous cell carcinoma of skin	0.00	0.00	0.00	0.00	0.00	0.00	1.47	0.00	0.81	0.00	1.45	0.00	5.95	3.63	0.00	16.95	35.43	0.00	1503
Salivary gland	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.06	0.00	0.00	0.00	0.00	0.00	0.00	9709
Skin other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.81	0.00	2.90	4.12	2.97	0.00	0.00	0.00	0.00	0.00	1744
Small intestine	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	0.00	0.00	0.00	2.97	0.00	6.38	0.00	0.00	0.00	1997
Stomach	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.34	0.81	0.00	2.90	8.25	2.97	0.00	0.00	0.00	35.43	0.00	1230
Testis	0.00	0.00	0.00	0.00	0.00	0.00	1.47	0.67	0.00	1.07	1.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4292
Tongue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.28	1.45	2.06	5.95	7.25	12.76	0.00	0.00	0.00	593

COLOURED MALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	0.00	0.00	0.00	0.00	0.00	28.62	0.00	0.00	26.69	0.00	46.67	143.96	117.68	262.71	195.15	658.29	0.00	0.00	25
All sites but skin	0.00	0.00	0.00	0.00	0.00	28.62	0.00	0.00	26.69	0.00	46.67	143.96	117.68	262.71	195.15	658.29	0.00	0.00	25
Anus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	46.67	0.00	117.68	0.00	0.00	0.00	0.00	0.00	122
Bladder	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	47.99	0.00	0.00	0.00	0.00	0.00	0.00	417
Larynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	87.57	0.00	0.00	0.00	0.00	229
Lung	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	47.99	0.00	0.00	0.00	0.00	0.00	0.00	417
Non Hodgkin lymphoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	26.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	750
Primary site unknown	0.00	0.00	0.00	0.00	0.00	28.62	0.00	0.00	0.00	0.00	0.00	0.00	0.00	87.57	0.00	0.00	0.00	0.00	173
Prostate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	47.99	0.00	87.57	195.15	0.00	0.00	0.00	61
Squamous cell carcinoma of skin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	658.29	0.00	0.00	25

WHITE MALES																			
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+	LR74
All sites	17.68	0.00	0.00	7.26	21.41	22.09	62.49	87.71	207.00	325.50	434.07	765.81	849.91	854.56	1295.72	1826.41	2645.28	2689.52	5
All sites but skin	17.68	0.00	0.00	7.26	14.27	14.73	41.66	71.26	108.95	223.78	277.32	444.66	571.62	583.46	789.85	1087.15	1834.63	1379.24	7
Anus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.09	12.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1167
Basal cell carcinoma	0.00	0.00	0.00	0.00	7.14	7.36	13.89	16.45	92.61	101.72	156.75	321.15	270.77	271.10	505.86	739.26	810.65	1310.28	12
Bladder	0.00	0.00	0.00	0.00	0.00	0.00	6.94	0.00	0.00	5.09	18.09	37.06	37.61	29.47	35.50	72.48	170.66	0.00	118
Bone	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.52	0.00	0.00	0.00	42.67	0.00	2660
Brain. CNS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15.26	0.00	6.18	0.00	0.00	0.00	14.50	0.00	0.00	933
Breast	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.45	5.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1898
Colorectal	0.00	0.00	0.00	0.00	7.14	0.00	0.00	0.00	16.34	5.09	30.14	37.06	52.65	64.83	79.87	72.48	42.67	0.00	69
Connective tissue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.87	0.00	0.00	0.00	2255
Haematology other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.87	14.50	0.00	0.00	2255
Hodgkin lymphoma	8.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.89	0.00	0.00	0.00	68.96	1358
Ill defined	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.79	17.75	0.00	0.00	0.00	678
Kidney	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.45	0.00	12.06	12.35	0.00	11.79	0.00	28.99	0.00	0.00	481
Larynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.45	5.09	0.00	0.00	0.00	11.79	0.00	14.50	0.00	0.00	896
Leukaemia	0.00	0.00	0.00	0.00	0.00	7.36	0.00	0.00	0.00	10.17	6.03	0.00	7.52	5.89	0.00	0.00	0.00	0.00	541
Lip	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.09	0.00	0.00	0.00	0.00	0.00	0.00	42.67	0.00	3930
Liver & Bile duct	0.00	0.00	0.00	0.00	0.00	0.00	6.94	0.00	0.00	10.17	0.00	24.70	7.52	11.79	17.75	0.00	42.67	0.00	254
Lung	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.48	5.45	20.34	18.09	24.70	22.56	47.15	35.50	86.97	0.00	0.00	112
Melanoma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.96	0.00	15.26	6.03	24.70	37.61	64.83	44.37	43.49	213.33	137.92	99
Mesothelioma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.09	0.00	0.00	0.00	0.00	0.00	0.00	42.67	0.00	3930
Mouth	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.03	6.18	7.52	0.00	8.87	0.00	0.00	0.00	700
Myeloma	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.09	0.00	6.18	7.52	0.00	8.87	0.00	0.00	0.00	724
Naso-Oropharynx	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.03	0.00	7.52	0.00	8.87	14.50	0.00	0.00	893
Non Hodgkin lymphoma	0.00	0.00	0.00	0.00	7.14	0.00	0.00	5.48	5.45	10.17	12.06	6.18	15.04	5.89	0.00	28.99	0.00	0.00	297

Oesophagus	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.89	5.09	6.03	12.35	22.56	5.89	17.75	28.99	0.00	0.00	249
Other specified	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.52	0.00	0.00	0.00	0.00	0.00	2660
Pancreas	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.18	0.00	11.79	26.62	28.99	0.00	0.00	449
Penis	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3670
Primary site unknown	8.84	0.00	0.00	7.26	0.00	0.00	6.94	0.00	5.45	0.00	12.06	49.41	30.09	41.25	35.50	57.98	0.00	137.92	102
Prostate	0.00	0.00	0.00	0.00	0.00	7.36	0.00	0.00	27.24	50.86	60.29	104.99	218.12	141.45	283.99	246.42	383.99	137.92	23
Squamous cell carcinoma of skin	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.96	10.89	15.26	54.26	67.93	67.69	106.08	124.25	304.40	810.65	827.54	44
Salivary gland	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.45	0.00	0.00	0.00	7.52	0.00	0.00	0.00	0.00	0.00	1543
Skin other	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20.34	0.00	0.00	15.04	0.00	17.75	0.00	42.67	68.96	377
Small intestine	0.00	0.00	0.00	0.00	0.00	0.00	6.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2882
Stomach	0.00	0.00	0.00	0.00	0.00	0.00	6.94	5.48	5.45	5.09	6.03	12.35	0.00	0.00	8.87	28.99	0.00	0.00	399
Testis	0.00	0.00	0.00	0.00	0.00	0.00	13.89	21.93	0.00	0.00	0.00	6.18	0.00	0.00	0.00	0.00	0.00	0.00	477
Thyroid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.96	0.00	5.09	6.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	906
Tongue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.03	0.00	0.00	5.89	0.00	0.00	0.00	0.00	1678

Frequency of Cancer by Age Group

ALL FEMALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	2375	0	5	7	4	14	16	38	113	215	241	326	205	262	230	228	203	133	66	69
All sites but skin	2095	0	5	7	4	14	16	36	108	207	234	302	188	236	205	180	157	102	45	49
Anus	26	0	0	0	0	0	0	0	3	4	7	5	1	0	3	1	1	1	0	0
Basal cell carcinoma	273	0	0	0	0	0	0	2	3	7	7	24	16	26	23	48	45	31	21	20
Bladder	13	0	0	0	0	0	0	0	0	1	0	2	2	2	3	0	2	0	0	1
Bone	3	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0
Brain, CNS	23	0	1	1	1	2	0	1	0	1	4	4	1	1	1	1	2	2	0	0
Breast	590	0	0	0	0	2	1	9	36	60	85	81	47	69	61	55	47	21	6	10
Burkitt lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Cervix	587	0	0	0	0	0	1	10	27	69	76	122	70	72	50	35	34	12	5	4
Colorectal	101	0	0	0	0	0	0	1	6	6	3	14	12	11	11	9	16	5	6	1
Connective tissue	13	0	0	0	1	1	1	0	2	1	0	1	2	1	1	0	0	2	0	0
Endocrine	3	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0
Eye	10	0	2	0	0	0	0	0	1	1	0	1	3	1	1	0	0	0	0	0
Gum	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Hodgkin lymphoma	11	0	0	0	1	2	1	0	1	1	3	0	1	0	0	0	0	1	0	0
Ill defined	8	0	0	0	0	0	0	0	0	2	1	3	0	0	0	1	1	0	0	0
Kaposi Sarcoma	20	0	0	0	0	0	0	3	3	3	6	1	0	2	0	1	1	0	0	0
Kidney	12	0	0	2	0	1	0	1	0	0	0	1	0	1	0	2	0	2	0	2
Larynx	4	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1	0	0	0	0

Leukaemia	17	0	2	2	1	0	1	1	0	4	0	1	1	0	0	1	0	2	0	1
Lip	2	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0
Liver & Bile duct	18	0	0	0	0	0	0	0	3	0	3	1	1	2	1	3	2	0	2	0
Lung	36	0	0	0	0	0	0	0	0	0	1	3	1	5	8	6	4	6	0	2
Melanoma	44	0	0	1	0	1	3	1	1	2	3	4	2	5	4	7	3	4	1	2
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Mouth	3	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	1	0	0
Myeloma	8	0	0	0	0	0	0	0	0	0	1	2	1	0	1	2	0	0	1	0
Naso-Oropharynx	8	0	0	0	0	0	1	0	1	0	0	1	1	3	0	1	0	0	0	0
Non Hodgkin lymphoma	37	0	0	1	0	0	0	2	4	4	5	1	9	4	1	2	1	2	0	1
Oesophagus	24	0	0	0	0	0	0	0	0	5	2	4	4	2	4	0	2	1	0	0
Other specified	16	0	0	0	0	0	1	0	1	1	0	1	2	4	1	0	0	1	2	2
Ovary	34	0	0	0	0	0	1	1	1	2	1	3	4	5	6	3	2	3	2	0
Pancreas	18	0	0	0	0	0	0	0	0	2	0	1	0	2	2	5	3	2	1	0
Primary site unknown	107	0	0	0	0	4	2	0	7	5	9	16	6	14	11	15	7	7	2	2
Squamous cell carcinoma of skin	90	0	0	0	0	0	0	1	0	3	2	5	2	6	9	8	10	12	14	18
Salivary gland	6	0	0	0	0	0	0	0	1	1	0	0	1	0	2	0	1	0	0	0
Skin other	9	0	0	0	0	0	0	2	0	0	1	0	2	0	0	1	0	2	0	1
Small intestine	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Stomach	17	0	0	0	0	0	2	0	0	2	0	2	1	0	2	2	4	2	0	0
Thyroid	13	0	0	0	0	0	1	0	3	0	0	2	1	3	0	1	0	1	1	0
Tongue	13	0	0	0	0	0	0	0	0	1	0	2	1	0	4	1	1	1	1	1
Uterus	65	0	0	0	0	0	0	0	0	4	3	2	5	11	11	14	8	6	0	1
Vagina	15	0	0	0	0	0	0	0	2	4	1	2	1	2	2	0	1	0	0	0
Vulva	74	0	0	0	0	0	0	2	5	17	15	12	4	6	5	1	3	3	1	0

ASIAN FEMALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	29	0	0	0	0	0	0	0	2	1	5	4	4	2	3	2	2	3	1	0
All sites but skin	28	0	0	0	0	0	0	0	2	1	4	4	4	2	3	2	2	3	1	0
Basal cell carcinoma	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Bladder	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Breast	10	0	0	0	0	0	0	0	2	1	1	2	1	0	2	0	1	0	0	0
Cervix	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Colorectal	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0
Liver & Bile duct	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Other specified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Primary site unknown	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0
Skin other	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Stomach	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Thyroid	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Tongue	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0
Uterus	4	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	1	0	0

BLACK FEMALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	1492	0	5	7	4	12	11	33	95	183	191	233	136	182	140	96	91	47	10	16
All sites but skin	1476	0	5	7	4	12	11	32	94	182	191	233	135	178	135	96	88	47	10	16
Anus	22	0	0	0	0	0	0	0	3	4	7	4	0	0	2	0	1	1	0	0
Basal cell carcinoma	10	0	0	0	0	0	0	1	0	0	0	0	0	4	3	0	2	0	0	0
Bladder	5	0	0	0	0	0	0	0	0	1	0	2	0	1	0	0	1	0	0	0
Bone	3	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	0	0	0
Brain, CNS	15	0	1	1	1	2	0	1	0	1	2	4	1	0	0	0	1	0	0	0
Breast	400	0	0	0	0	2	0	9	30	52	59	57	31	50	34	27	27	13	3	6
Burkitt lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Cervix	518	0	0	0	0	0	1	9	27	60	73	102	59	69	46	28	28	9	4	3
Colorectal	45	0	0	0	0	0	0	0	5	5	0	9	10	4	6	1	4	0	0	1
Connective tissue	10	0	0	0	1	1	1	0	1	1	0	1	1	0	1	0	0	2	0	0
Endocrine	3	0	0	0	0	0	0	0	1	0	0	2	0	0	0	0	0	0	0	0
Eye	10	0	2	0	0	0	0	0	1	1	0	1	3	1	1	0	0	0	0	0
Gum	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Hodgkin lymphoma	9	0	0	0	1	1	1	0	1	1	3	0	1	0	0	0	0	0	0	0
Ill defined	6	0	0	0	0	0	0	0	0	2	1	1	0	0	0	1	1	0	0	0
Kaposi Sarcoma	20	0	0	0	0	0	0	3	3	3	6	1	0	2	0	1	1	0	0	0
Kidney	8	0	0	2	0	1	0	1	0	0	0	0	0	1	0	1	0	1	0	1
Larynx	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0
Leukaemia	14	0	2	2	1	0	0	0	0	4	0	1	1	0	0	1	0	2	0	0

Lip	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Liver & Bile duct	13	0	0	0	0	0	0	0	3	0	2	1	1	2	1	1	2	0	0	0
Lung	23	0	0	0	0	0	0	0	0	0	1	3	1	3	6	6	0	1	0	2
Melanoma	6	0	0	1	0	0	0	0	0	0	1	2	0	0	1	1	0	0	0	0
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Mouth	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Myeloma	6	0	0	0	0	0	0	0	0	0	1	2	0	0	1	2	0	0	0	0
Naso-Oropharynx	6	0	0	0	0	0	1	0	1	0	0	1	1	2	0	0	0	0	0	0
Non Hodgkin lymphoma	29	0	0	1	0	0	0	2	4	2	5	0	8	3	1	1	1	1	0	0
Oesophagus	21	0	0	0	0	0	0	0	0	5	2	4	3	2	3	0	2	0	0	0
Other specified	11	0	0	0	0	0	1	0	1	1	0	1	0	4	0	0	0	1	1	1
Ovary	21	0	0	0	0	0	1	1	1	2	1	2	2	3	4	2	0	2	0	0
Pancreas	8	0	0	0	0	0	0	0	0	2	0	0	0	2	0	1	2	1	0	0
Primary site unknown	65	0	0	0	0	4	2	0	4	3	7	12	5	8	5	6	5	4	0	0
Squamous cell carcinoma of skin	12	0	0	0	0	0	0	1	0	3	1	3	0	0	1	0	0	0	1	2
Salivary gland	6	0	0	0	0	0	0	0	1	1	0	0	1	0	2	0	1	0	0	0
Skin other	4	0	0	0	0	0	0	2	0	0	1	0	1	0	0	0	0	0	0	0
Stomach	10	0	0	0	0	0	2	0	0	2	0	1	0	0	2	1	1	1	0	0
Thyroid	4	0	0	0	0	0	1	0	1	0	0	1	0	1	0	0	0	0	0	0
Tongue	5	0	0	0	0	0	0	0	0	1	0	0	0	0	3	1	0	0	0	0
Uterus	53	0	0	0	0	0	0	0	0	3	1	2	2	10	10	13	7	5	0	0
Vagina	14	0	0	0	0	0	0	0	2	4	1	2	1	2	1	0	1	0	0	0
Vulva	70	0	0	0	0	0	0	2	5	17	14	11	3	6	5	1	2	3	1	0

COLOURED FEMALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	35	0	0	0	0	0	2	0	1	2	4	4	6	3	8	3	2	0	0	0
All sites but skin	35	0	0	0	0	0	2	0	1	2	4	4	6	3	8	3	2	0	0	0
Brain, CNS	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Breast	14	0	0	0	0	0	1	0	1	1	2	1	2	0	5	1	0	0	0	0
Cervix	7	0	0	0	0	0	0	0	0	0	0	2	2	1	0	2	0	0	0	0
Colorectal	4	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0
Lung	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Melanoma	2	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0
Non Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Ovary	3	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0
Primary site unknown	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Vulva	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0

WHITE FEMALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	810	0	0	0	0	2	3	5	15	29	41	83	58	75	78	126	105	82	55	53
All sites but skin	550	0	0	0	0	2	3	4	11	22	35	59	43	53	58	78	63	52	34	33
Anus	4	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	0	0	0
Basal cell carcinoma	259	0	0	0	0	0	0	1	3	7	6	24	15	22	20	48	42	30	21	20
Bladder	6	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	1	0	0	1
Brain, CNS	7	0	0	0	0	0	0	0	0	0	2	0	0	1	0	1	1	2	0	0
Breast	165	0	0	0	0	0	0	0	3	6	23	21	13	19	20	27	18	8	3	4
Cervix	59	0	0	0	0	0	0	1	0	9	3	17	9	2	4	4	5	3	1	1
Colorectal	50	0	0	0	0	0	0	1	1	1	3	4	1	6	4	7	11	5	6	0
Connective tissue	3	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0
Hodgkin lymphoma	2	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Ill defined	2	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0
Kidney	4	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	1
Larynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0
Leukaemia	3	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	1
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Liver & Bile duct	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	2	0
Lung	12	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0	3	5	0	0
Melanoma	35	0	0	0	0	1	2	1	1	2	2	1	2	5	3	6	2	4	1	2
Mouth	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0
Myeloma	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0

Naso-Oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
Non Hodgkin lymphoma	6	0	0	0	0	0	0	0	0	0	1	0	1	0	1	0	1	0	1	0	1
Oesophagus	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0
Other specified	4	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	0	1
Ovary	10	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	2	1	2	0
Pancreas	10	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	4	1	1	1	0
Primary site unknown	39	0	0	0	0	0	0	0	3	2	0	4	1	5	6	9	2	3	2	2	2
Squamous cell carcinoma of skin	78	0	0	0	0	0	0	0	0	0	1	2	2	6	8	8	10	12	13	16	16
Skin other	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	1
Small intestine	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Stomach	6	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	3	0	0	0
Thyroid	8	0	0	0	0	0	0	0	2	0	0	1	0	2	0	1	0	1	1	1	0
Tongue	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	1	1
Uterus	8	0	0	0	0	0	0	0	0	1	1	0	3	0	1	0	1	0	0	0	1
Vagina	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Vulva	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0	0

ALL MALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	1741	0	12	4	1	10	7	11	34	60	93	142	143	227	229	243	225	168	81	51
All sites but skin	1362	0	12	4	1	10	6	10	31	55	73	119	115	172	188	197	164	114	59	32
Anus	19	0	0	0	0	0	0	0	0	3	1	5	5	2	1	0	0	1	1	0
Basal cell carcinoma	372	0	0	0	0	0	1	1	2	4	19	23	28	54	39	46	60	54	22	19
Bladder	45	0	0	0	0	0	0	0	1	0	0	4	7	9	6	5	4	5	4	0
Bone	6	0	0	1	0	2	0	0	1	0	0	0	0	0	1	0	0	0	1	0
Brain, CNS	12	0	3	0	0	0	0	0	0	0	2	3	0	1	0	2	0	1	0	0
Breast	11	0	0	0	0	0	0	0	0	0	3	1	1	0	2	3	1	0	0	0
Burkitt lymphoma	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Colorectal	112	0	0	0	0	0	3	0	0	3	5	11	12	15	15	19	15	9	2	3
Connective tissue	7	0	0	1	0	1	0	0	1	0	0	1	0	1	0	0	1	0	1	0
Endocrine	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Eye	10	0	1	0	0	0	0	0	0	1	1	4	1	2	0	0	0	0	0	0
Haematology other	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Hodgkin lymphoma	24	0	2	1	0	0	1	1	1	2	4	4	2	1	3	1	0	0	0	1
Ill defined	11	0	0	0	0	0	0	0	2	0	1	1	0	0	0	2	3	1	1	0
Kaposi Sarcoma	28	0	0	0	0	0	0	2	4	3	8	4	5	0	1	0	0	1	0	0
Kidney	15	0	1	0	0	0	0	0	0	0	1	1	3	3	2	2	0	2	0	0
Larynx	27	0	0	0	0	0	0	0	0	0	2	4	2	2	4	10	1	2	0	0
Leukaemia	16	0	0	0	0	1	0	2	0	1	1	3	1	2	1	3	1	0	0	0
Lip	4	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	1	0
Liver & Bile duct	25	0	1	0	0	0	0	0	3	0	3	2	0	5	2	3	4	0	2	0

Lung	71	0	0	0	0	0	0	1	1	6	3	14	8	7	8	9	6	8	0	0
Melanoma	46	0	0	0	0	0	0	0	0	4	1	3	1	4	6	12	5	3	5	2
Mesothelioma	6	0	0	0	0	0	0	0	0	0	0	1	0	0	2	1	0	0	2	0
Mouth	10	0	0	0	0	0	0	0	1	0	0	0	1	3	1	2	2	0	0	0
Myeloma	14	0	0	0	0	0	0	0	0	1	1	2	2	4	2	0	2	0	0	0
Naso-Oropharynx	16	0	0	0	0	0	0	0	2	0	2	1	2	4	2	1	1	1	0	0
Non Hodgkin lymphoma	44	0	1	0	0	0	1	0	1	7	4	7	9	3	3	5	0	2	0	1
Oesophagus	31	0	0	0	0	0	0	0	0	3	3	3	2	8	4	2	2	4	0	0
Other specified	8	0	1	0	0	0	0	0	0	1	0	2	0	2	1	0	1	0	0	0
Pancreas	14	0	0	0	0	0	0	0	1	0	0	1	0	5	0	2	3	2	0	0
Penis	12	0	0	0	0	0	0	0	2	0	1	4	1	2	1	0	0	1	0	0
Primary site unknown	84	0	1	1	1	6	0	2	2	1	7	2	8	16	10	14	5	4	2	2
Prostate	426	0	0	0	0	0	0	1	1	5	13	14	22	49	93	76	86	41	15	10
Squamous cell carcinoma of skin	132	0	0	0	0	0	0	0	2	2	3	3	11	11	11	19	15	23	20	12
Salivary gland	3	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0	0	0
Skin other	17	0	0	0	0	0	0	0	0	1	1	4	2	2	3	0	2	0	1	1
Small intestine	4	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	1	0	0	0
Stomach	22	0	0	0	0	0	0	0	1	3	2	1	3	7	1	0	1	2	1	0
Testis	13	0	0	0	0	0	1	0	4	5	0	1	1	1	0	0	0	0	0	0
Thyroid	5	0	0	0	0	0	0	0	0	3	0	1	1	0	0	0	0	0	0	0
Tongue	14	0	0	0	0	0	0	0	0	0	0	4	2	1	2	3	2	0	0	0

ASIAN MALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	19	0	0	0	0	0	3	0	0	2	0	1	2	1	1	2	3	3	0	1
All sites but skin	19	0	0	0	0	0	3	0	0	2	0	1	2	1	1	2	3	3	0	1
Colorectal	5	0	0	0	0	0	2	0	0	0	0	1	1	0	0	0	0	1	0	0
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Lung	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Melanoma	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Myeloma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Non Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Primary site unknown	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Prostate	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0
Squamous cell carcinoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Stomach	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Testis	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Thyroid	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0

BLACK MALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	734	0	10	4	1	9	1	7	24	40	53	77	65	99	113	92	72	38	18	11
All sites but skin	714	0	10	4	1	9	1	7	24	39	51	74	65	96	110	92	69	35	16	11
Anus	13	0	0	0	0	0	0	0	0	2	1	4	2	2	0	0	0	1	1	0
Basal cell carcinoma	16	0	0	0	0	0	0	0	0	0	2	3	0	2	2	0	2	3	2	0
Bladder	10	0	0	0	0	0	0	0	0	0	0	3	4	2	1	0	0	0	0	0
Bone	4	0	0	1	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Brain, CNS	7	0	3	0	0	0	0	0	0	0	2	0	0	0	0	2	0	0	0	0
Breast	9	0	0	0	0	0	0	0	0	0	2	0	1	0	2	3	1	0	0	0
Burkitt lymphoma	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Colorectal	58	0	0	0	0	0	0	0	0	3	2	9	6	9	8	8	6	3	1	3
Connective tissue	6	0	0	1	0	1	0	0	1	0	0	1	0	1	0	0	0	0	1	0
Endocrine	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Eye	10	0	1	0	0	0	0	0	0	1	1	4	1	2	0	0	0	0	0	0
Hodgkin lymphoma	21	0	1	1	0	0	1	1	1	2	4	4	2	1	3	0	0	0	0	0
Ill defined	7	0	0	0	0	0	0	0	2	0	1	1	0	0	0	0	1	1	1	0
Kaposi Sarcoma	28	0	0	0	0	0	0	2	4	3	8	4	5	0	1	0	0	1	0	0
Kidney	6	0	1	0	0	0	0	0	0	0	0	1	1	1	2	0	0	0	0	0
Larynx	20	0	0	0	0	0	0	0	0	0	1	3	1	2	4	7	1	1	0	0
Leukaemia	10	0	0	0	0	1	0	1	0	1	1	1	0	2	0	2	1	0	0	0
Lip	2	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0
Liver & Bile duct	12	0	1	0	0	0	0	0	2	0	3	0	0	1	1	1	2	0	1	0

Lung	35	0	0	0	0	0	0	1	1	5	2	10	5	2	5	1	2	1	0	0
Melanoma	4	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	0	0	0	0
Mesothelioma	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	1	0
Mouth	5	0	0	0	0	0	0	0	1	0	0	0	0	2	0	2	0	0	0	0
Myeloma	9	0	0	0	0	0	0	0	0	1	1	1	2	3	1	0	0	0	0	0
Naso-Oropharynx	12	0	0	0	0	0	0	0	2	0	2	1	1	4	1	1	0	0	0	0
Non Hodgkin lymphoma	28	0	1	0	0	0	0	0	1	6	1	5	7	2	1	4	0	0	0	0
Oesophagus	17	0	0	0	0	0	0	0	0	3	1	2	1	6	1	1	0	2	0	0
Other specified	7	0	1	0	0	0	0	0	0	1	0	2	0	2	0	0	1	0	0	0
Pancreas	6	0	0	0	0	0	0	0	1	0	0	1	0	4	0	0	0	0	0	0
Penis	11	0	0	0	0	0	0	0	2	0	0	4	1	2	1	0	0	1	0	0
Primary site unknown	45	0	0	1	1	5	0	1	0	1	6	2	6	8	6	5	1	0	2	0
Prostate	261	0	0	0	0	0	0	0	1	5	8	4	12	31	63	49	51	23	6	8
Squamous cell carcinoma of skin	9	0	0	0	0	0	0	0	2	0	1	0	1	0	2	1	0	1	1	0
Salivary gland	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Skin other	7	0	0	0	0	0	0	0	0	1	1	0	2	2	1	0	0	0	0	0
Small intestine	3	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0	0
Stomach	11	0	0	0	0	0	0	0	0	2	1	0	2	4	1	0	0	0	1	0
Testis	5	0	0	0	0	0	0	0	2	1	0	1	1	0	0	0	0	0	0	0
Tongue	12	0	0	0	0	0	0	0	0	0	0	4	1	1	2	2	2	0	0	0

COLOURED MALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	12	0	0	0	0	0	0	1	0	0	1	0	1	3	1	3	1	1	0	0
All sites but skin	12	0	0	0	0	0	0	1	0	0	1	0	1	3	1	3	1	1	0	0
Anus	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0
Bladder	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Lung	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Non Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Primary site unknown	2	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0
Prostate	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0
Squamous cell carcinoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0

WHITE MALES																				
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-85	85+
All sites	963	0	2	0	0	1	3	3	9	16	38	64	72	124	113	145	146	126	62	39
All sites but skin	610	0	2	0	0	1	2	2	6	13	20	44	46	72	76	99	89	75	43	20
Anus	3	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0
Basal cell carcinoma	350	0	0	0	0	0	1	1	2	3	17	20	26	52	36	46	57	51	19	19
Bladder	34	0	0	0	0	0	0	0	1	0	0	1	3	6	5	5	4	5	4	0
Bone	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0
Brain, CNS	5	0	0	0	0	0	0	0	0	0	0	3	0	1	0	0	0	1	0	0
Breast	2	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0
Colorectal	49	0	0	0	0	0	1	0	0	0	3	1	5	6	7	11	9	5	1	0
Connective tissue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Haematology other	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
Hodgkin lymphoma	3	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
Ill defined	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0	0
Kidney	9	0	0	0	0	0	0	0	0	0	1	0	2	2	0	2	0	2	0	0
Larynx	5	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	0	1	0	0
Leukaemia	6	0	0	0	0	0	0	1	0	0	0	2	1	0	1	1	0	0	0	0
Lip	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0
Liver & Bile duct	13	0	0	0	0	0	0	0	1	0	0	2	0	4	1	2	2	0	1	0
Lung	34	0	0	0	0	0	0	0	0	1	1	4	3	4	3	8	4	6	0	0
Melanoma	41	0	0	0	0	0	0	0	0	2	0	3	1	4	5	11	5	3	5	2
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0

Mouth	4	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0
Myeloma	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	1	0	0	0
Naso-Oropharynx	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	0	0	
Non Hodgkin lymphoma	13	0	0	0	0	0	1	0	0	1	1	2	2	1	2	1	0	2	0	0	
Oesophagus	14	0	0	0	0	0	0	0	0	0	2	1	1	2	3	1	2	2	0	0	
Other specified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
Pancreas	8	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	3	2	0	0	
Penis	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	
Primary site unknown	35	0	1	0	0	1	0	0	1	0	1	0	2	8	4	7	4	4	0	2	
Prostate	156	0	0	0	0	0	0	1	0	0	5	10	10	17	29	24	32	17	9	2	
Squamous cell carcinoma of skin	120	0	0	0	0	0	0	0	0	2	2	3	9	11	9	18	14	21	19	12	
Salivary gland	2	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	
Skin other	10	0	0	0	0	0	0	0	0	0	0	4	0	0	2	0	2	0	1	1	
Small intestine	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	
Stomach	10	0	0	0	0	0	0	0	1	1	1	1	1	2	0	0	1	2	0	0	
Testis	7	0	0	0	0	0	0	0	2	4	0	0	0	1	0	0	0	0	0	0	
Thyroid	4	0	0	0	0	0	0	0	0	2	0	1	1	0	0	0	0	0	0	0	